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ABSTRACT
DETERMINATION OF PANCREATIC AND SALIVARY AMYLASE 
BY ENZYME IMMUNOASSAY AND THEIR PREVALENCE 
IN HYPERAMYLASEMIC PATIENTS
Sandra Borgens Ward 
Old Dominion University, 1994 
Director: Dr. James H. Yuan
Currently, amylase determinations are nonspecific for the organ source and are 
based entirely on the enzymatic properties of amylase to produce a measurable 
product or byproduct. The determination of pancreatic amylase is important in the 
diagnosis of acute pancreatitis. Most commercially available tests for amylase employ 
the measurement of the change in NADH absorbance at 280 nm or of the 
p-nitrophenol released from a maltotetrose substrate. These are nonspecific 
measurements of pancreatic amylase and often necessitate other tests to be run such as 
a serum lipase.
The two predominant isoenzymes of amylase are pancreatic (p-amylase) and 
salivary (s-amylase); the most important of which is pancreatic. Pancreatic amylase to 
date is determined by the removal of salivary amylase by monoclonal antibody, wheat 
germ, or ion-exchange chromatography. Also amylase isoenzymes are determined by 
electrophoresis. These methods are time consuming and lack either specificity or 
quantification capability. There is a 1% difference in the amino acid sequences of 
pancreatic and salivary amylase. These structural differences between pancreatic and 
salivary amylase are small but significant enough that they should enable a 
monoclonal antibody to be produced for each isoenzyme.
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A sensitive and specific microwell assay based on sandwich technique for the 
quantitative determination of the p-amylase and s-amylase was developed. Microwells 
were utilized for the solid-phase immobilization of the amylase inhibitor 
cycloheptaamylose (CHA) which was coupled to bovine serum albumin (BSA) by 
carbodiimide coupling. Monoclonal antibodies were produced against p-amylase and 
s-amylase (PAb and SAb). These were purified by Protein-A affinity chromatography 
and then coupled to horseradish peroxidase (HRPO) by carbodiimide coupling. The 
microwells which were coated with oxidized CHA-BSA (CHA-BSA) were incubated 
with patient’s serum and then allowed to react with the PAb-HRPO and SAb-HRPO.
This EIA method is able to distinguish between p-amylase and s-amylase 
quantitatively, rapidly and has the capability for automation. The correlation 
coefficients for human serum samples were 0.920 and 0.867 for p-amylase and 
s-amylase when comparing this EIA method and protein electrophoresis then staining 
for amylase. The limit of detection was determined to be 8 U/L for p-amylase and 16 
U/L for s-amylase. The percent coefficient of variation for p-amylase was found to be 
7.79% for the normal control and 6.28% for the abnormal control. The percent 
coefficient of variation for s-amylase was found to be 9.42% for the normal control 
and 9.29% for the abnormal control.
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1. Chemical properties amylase
Pancreatic a amylase (a-l,4-glucan 4-glucanohydrolase EC 3.2.1.1) is present 
in two equally active forms (I and II). To date, structural studies have been 
performed on porcine pancreatic amylase. Its molecular weight has been calculated to 
be 54,967.12 It is also not significantly glycosylated.1 Porcine pancreatic a-amylase 
consists of three domains. The N-terminus contains: domain A, the largest portion, 
and domain B. Domain A folds into a typical (alpha/beta)8 barrel structure. Between 
the third beta-strand and the third helix of domain A lies domain B. This region has 
two antiparallel beta-sheets and a long loop, whose internal structure is not as regular. 
Domain B is involved in substrate binding.3 Binding studies indicate that there are two 
binding sites: one in a deep cleft that exists 3 nm from the carboxyl end of the 
alpha/beta barrel, which is believed to be the active site; the other binding site is 
believed to be on the surface of the molecule about 2 nm away from the active site 
region.4 A globular C domain exists in the C-terminal region. It consists of a chain 
folded into an 8-stranded antiparallel beta-barrel.
A calcium ion appears to form an ionic bridge between domain A and B.3 The 
attachment of the calcium ion is essential for the structural integrity of amylase. 
Calcium ions can be replaced by strontium or barium ions. Chloride ions are known 
to be required for amylase activity.4,5 Chloride’s attachment is at the center of the
1
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alpha/beta barrel and is bound to a specific lys residue. Chloride can be replaced by a 
bromide ion.6
Robyt and French studied the binding sites of maltotriose (G3) through 
maltooctaose (G8) with the use of 14C label in the reducing glucose unit. Maltodextrin 
G3 was cleaved at bond one and two from the reducing end with the highest 
frequency at bond one. As the length increased to G4, bonds one and two were still 
cleaved; however, the highest frequency became bond two. Cleavage of maltodextrins 
G5 through G7 remained at bond 2; however, the maximum cleavage shifted with G8 
to bond 3.
The active binding site was therefore proposed to bind a maximum of five 
glucose units. Also, the binding of the substrate appeared to be polar with the 
reducing end to the right of the catalytic groups. With G5 and higher 
oligosaccharides, the cleavage was explained by the tendency of the molecule to 
occupy as fully as possible the entire binding site; thus, the ends overlap, and 
cleavage was at the number three bond. This was supported by the fact that G5 was 
resistant to cleavage of all bonds except number two.
As the concentration of the substrates increased, the products shifted. The data 
supported the fact thaf at low concentrations of G3 the products are due to hydrolysis 
since G1 was produced at a faster rate than G2. At high concentrations, G2 was 
formed at a faster rate. This supports the hypothesis that the products are the result of 
condensation of two G3 molecules to produce a G6, which subsequently undergoes 
hydrolysis to give three G2’s.
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Maltodextrin G4 demonstrates a concentration dependence of the product 
distribution; however, the results are not as easily interpreted. The most reasonable 
explanation was still that a condensation reaction takes place initially,’ and then 
hydrolysis takes place. The frequency of cleavage suggested that the most stable 
binding favors formation with cleavage at bond three.7
There is a 7% difference in the amino acid sequences of the two predominant 
isoenzymes, salivary (s-amylase) and pancreatic amylase (p-amylase).8 They also 
differ in their activation energies and enthalpy changes.9 Electrophoresis yields the 
following isoenzymes of amylase: two pancreatic forms (P, and P2) and sometimes a 
third (P3), and two salivary forms (S, and S )̂.10 P3 is not found in normal pancreatic 
tissue but does occur in acute pancreatitis. The most common isoforms found are P2 
and S,. On migration on cellulose acetate and agarose S2 migrates closest to the 
anode, followed by S,, P3 if  present, P2 then P,.u
2. Sources of amylase
Human amylase is found in a variety of sources: pancreas, saliva, serum, 
urine, tears, breast milk, sweat, amniotic fluid, ovary, fallopian tubes and testes.1213 
The two most concentrated areas of amylase are the salivary glands and the pancreas14 
with the following values: parotid 1710 ±  897 U/g, submandibular 605 ±  354 U/g, 
and pancreas (258 + 137 U/g).11 Normal pancreatic tissue contains no s-amylase.15 
Normal total serum amylase is 25-125 U/L.12
Compared to the pancreas other tissues of the digestive tract contain 1/35 to 
1/45 the amount of amylase. The amylase that is present in these tissues is composed
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of 25% p-amylase and 75% s-amylase.15 Values of other tissues contain 1/100 to 
1/1000 less amylase as compared to the salivary glands and pancreas. Tissues that 
contain more than 90% p-amylase are the pancreas, jejunum, liver, placenta, testis, 
skeletal muscle, and spleen. Only the salivary and thyroid contained more than 90% 
of the s-amylase. All the other tissues contain mixtures of the two isoenzymes.11
Amylase is eliminated from the body via the glomerulus of the kidney and is 
not reabsorbed by the tubules.16 Therefore, urinary amylase levels reflect the serum 
level since the enzyme is not usually reabsorbed by the tubule except in renal tubular 
damage. Toxic compounds like the proteolytic enzymes of pancreatitis and ethanol can 




(1) Acute pancreatitis 
At one time hyperamylasemia was believed to be an exclusive indicator of 
pancreatic or salivary disease.18 The determination of p-amylase is still important in 
the diagnosis of acute pancreatitis.19 Causes of acute pancreatitis include obstruction, 
vascular disorders, trauma, toxins and a variety of metabolic disorders. The one 
common factor of all forms of acute pancreatitis is the increased permeability of the 
cell membrane and the autodigestion of the pancreatic proteolytic enzymes.20 Increase 
of serum amylase is the result of an increased rate of entry into the circulation and/or 
the decreased clearance of this enzyme. Although the pancreas and salivary glands are
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the two sources with the greatest amount of amylase,14 conditions other than 
pancreatitis and salivary disease have now been attributed to hyperamylasemia: such 
as, tumors of the lung, ovary,12 and breast;21 intestinal obstruction or inflammation; 
common-duct stones; hepatitis; facial or abdominal trauma22; autoimmune diseases;23 
chronic alcoholism; postoperative cardiopulmonary bypass; eating disorders; lactic 
acidosis; renal failure; macroamylasemia; and total body irradiation.24
In a comprehensive study of 368 patients over a 4 year period, the incidence 
of acute pancreatitis revealed: 56% related to gallstones, 16% to alcohol, and 28% 
idiopathic.25 A similar study showed slightly different percentages: 55% alcohol 
abuse, 27% gallstones, 6% pancreatic cancer, 12% miscellaneous.26 One study in 
Scotland showed the most common etiology of pancreatitis to have been biliary tract 
disease (30% of the males; 53% of the females). Pancreatitis related to alcohol 
occurred in 27% of the males, but in only 3% of the females. The most common 
complication was pancreatic pseudocysts, then pancreatic abscesses, renal failure, 
respiratory failure, and last disseminated intravascular coagulation.27
Sources of hyperamylasemia in a study by Dougherty showed 32% was due to 
gallstones, 49% alcoholic patients, and 19% other. In the gallstone patient group their 
amylase levels were significantly higher than the non gallstone groups; also the serum 
amylase decreased significantly in 24 hours. On surgery no or little pancreatitis was 
found in the gallstone group.28
Certainly the two most common groups are biliary or alcohol related. The 
migration of a gallstone causing the blocking of the ampulla of Vater can cause a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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gallstone pancreatitis.29 In some individuals, the ampulla of Vater is shared with the 
bile duct. In others it is separate but lies within close proximity.20 This diagnosis can 
be made based on history, physical exam and a serum amylase above 1000 IU/L, 
ultrasound, and CT scans.29
With the high correlation to alcohol abuse one would think that the reciprocal 
would be true: individuals with alcohol abuse have a higher incidence of pancreatic 
disease than the normal population. However, in a study of individuals arrested for 
drunk driving, it was found that pancreatic enzyme levels were twice normal in only 
3/300; whereas, hepatic enzymes were twice normal in 31/300. It was concluded that 
there were other factors besides alcohol that predisposed persons to acute pancreatitis 
and that the liver is more sensitive to alcohol abuse than the pancreas.30
Pancreatitis first presents itself with the following symptoms (in order of their 
prevalence): epigastric pain, localized or generalized tenderness, nausea and vomiting, 
fever, palpable mass and ascites.31 Symptoms are similar with the most common 
complaint being abdominal pain.32,33 Most helpful in diagnosis was hyperamylasemia; 
then elevated amylase/creatinine clearance ratio (C^/CJ.34 Lipase values are also 
often included.35 Autopsies over a five year period showed that out of 43 patients 
having acute pancreatitis, the disease was first diagnosed at autopsy in 30% of the 
cases. The diagnosis could have been present on admission in over half of these. 
Alcoholism, biliary tract disease, and surgery around the pancreatic area were among 
the most common causes. Abdominal pain was present in only one patient. Amylase 
levels were determined in 25% of the cases, but only 10% had amylase values in the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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diagnostic range (equal or greater than three time the upper limit.36 Wilson and Imrie 
raised the question why the diagnosis of acute pancreatitis was missed so frequently.
In their review of deaths due to acute pancreatitis over a 10 year period, acute 
pancreatitis was not diagnosed until autopsy in 33% of the cases.37 Only 7% had 
abdominal pain. The majority, 68%, presented an atypical picture with another known 
or suspected condition or were a postoperative result. Amylase determinations were 
made in only 9% of the cases. They concluded that non-diagnosis was most often due 
to the lack of considering acute pancreatitis as a cause; hence, no diagnostic test that 
would reveal acute pancreatitis was performed.37
(2) Predisposed groups
Some groups of individuals have been identified to be predisposed to 
hyperamylasemia and/or pancreatitis. In homozygous sickle cell patients, it was found 
that 50% had elevated serum amylase values. This seems to suggest that they may be 
predisposed to chronic pancreatitis.38
Studies by Prinz have led to the conclusion that whereas infarction can induce 
inflammation and necrosis of the pancreas, ischemia may aggravate but does not cause 
pancreatitis.39 Also in a study of 52 patients with postoperative pancreatitis, 30 had 
previous procedures near the pancreas. The most common procedures were: biliary, 
colectomy and intestinal resection.40
(3) Cardiopulmonary bypass
Of particular note is the high incidence of hyperamylasemia and/or pancreatitis 
related to cardiopulmonary bypass surgery. In a study of three hundred patients
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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undergoing cardiopulmonary bypass, 32% developed hyperamylasemia. Within this 
group 58% were asymptomatic and had normal lipase, 33% had subclinical 
pancreatitis, and 8% actually had acute pancreatitis. Isoamylase studies indicated that 
the hyperamylasemia was not due to p-amylase. Mortality was higher in patients with 
hyperamylasemia.41 A study by Chang of 75 patients had similar results. 
Hyperamylasemia was seen in 36% of the patients. Of these patients, 3 out of the 27, 
developed acute pancreatitis. Analysis of these patients revealed that coronary artery 
disease predisposed a patient to post bypass hyperamylasemia. This phenomena has to 
be closely monitored since there is such a high incidence of non pancreatic 
hyperamylasemia, and yet the possibility of acute pancreatitis existed.42 Some reports 
suggest ischemia may be the cause of a greater risk of developing pancreatitis after 
undergoing cardiopulmonary bypass, but this has not been proven.43
Evidence that associates the preoperative administration of calcium chloride in 
cardiac surgery to have a high correlation with hyperamylasemia has also been 
implicated. Fernandez analyzed 300 patients undergoing cardiopulmonary bypass and 
reported "pancreatic cellular injury was significantly associated with preoperative 
renal insufficiency, valve surgery, postoperative hypotension, and preoperative 
administration of calcium chloride. "43 The risk of pancreatic cellular injury was also 
determined to be dose related to the calcium chloride. Administration of more than 
800 mg of calcium chloride per square meter of body-surface area appeared to be a 
predictor and possibly the cause of pancreatic cellular injury.43
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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In cardiac surgery, hyperamylasemia was seen in 36% of patients with bypass 
surgery, 59% of patients with valve replacement, and 69% undergoing both 
procedures. Lipase was increased in 30% of the cardiac surgeries. It was found that 
36% of the patients had an increase in s-amylase, which also correlated with the 
severity of pleural effusion. This may have been due to the absorbance of s-amylase 
from pleural fluid and/or from aspirated salivary secretions.44
In children with open heart surgery, it was found in a five year study that 54 
patients had elevated amylase values or clinical pancreatitis following surgery. Of 
these 33 had elevated amylase values only. The remaining exhibited pancreatitis along 
with elevated amylase values. The etiology was proposed to be vascular in origin.45
(4) Renal insufficiency
Another cause of hyperamylasemia is abnormal renal function. In 1987,
Bardella reported that 33 out of 37 chronic renal failure patients had elevated amylase 
levels, which correlated to the duration of the chronic renal failure. Pancreatic 
amylase, however, was only slightly elevated in three of these patients. Blood urea 
nitrogen (BUN) and serum creatinine showed no correlation to serum amylase.46 
Values of amylase, along with lipase and trypsin, can become elevated when the 
creatinine clearance is less than 50 mL/min.47 In chronic renal failure both the 
amylase values and the Cm/Ccr are increased; however, the p-amylase to s-amylase 
ratio is normal.48 These elevated amylase and lipase values have been reported in 
chronic renal failure patients in the absence of clinical pancreatitis. However, amylase 
values of greater than threefold in peritoneal fluid may be indicative of pancreatitis.49
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Interestingly, the total amylase was found to be significantly elevated in 34 end-stage 
renal disease and was not reduced after hemodialysis. However, serum lipase, which 
was likewise increased before dialysis, increased further after dialysis. The increase in 
lipase correlated with the cumulative doses of heparin. P3 isoamylase was normal in 
all patients.50
(5) Endoscopic retrograde cholangiopancretography
Endoscopic retrograde pancreatography (ERCP) is most helpful in determining 
if blunt trauma injury to the pancreas has caused any ductal injury.51 However, this 
procedure is not without its inherent problems. The first is that ERCP has been shown 
to elevate all of the major pancreatic enzymes (serum amylase; lipase; trypsin; 
elastase; serum alpha 1-antitrypsin and alpha 2-macroglobulin, two major pancreatic 
protease inhibitors) in a study of 25 patients undergoing this procedure. The second is 
that in three patients pancreatitis was induced by the ERCP.52 This ERCP induced 
pancreatitis is not that uncommon. In another study the incidence was even higher. In 
the follow up of 31 patients undergoing ERCP, 11 developed pancreatitis. The 
incidence was the highest in which maneuvers, such as stent placement and balloon 
dilation, were performed.53
(6) Eating disorders
In eating disorders, such as anorexia nervosa and bulimia, amylase levels as 
high as 3000 U/L have been seen; however, p-amylase, lipase, and trypsinogen were 
all normal.54 A study of 17 patients with eating disorders revealed that out of the six
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patients with hyperamylasemia, five had increased s-amylase while all had normal 
lipase and p-amylase.55
(7) Macroamylasemia
The first reported case of hyperamylasemia due to the formation of an 
amylase-globulin complex was by Wilding in 1964.56 The term "macroamylase" was 
first used by Berk in 1967 to describe persistently elevated serum amylase without 
hyperamylasuria.56,57 Early sources indicated a preponderance of the s-amylase 
coupled to the antibody;12 however, more recent sources seem to indicate that the 
amylase in macroamylase has an equal distribution of and p-amylase.58 The antibody 
involved in macroamylase formation appears to be a monoclonal antibody.58 It has 
been reported to be IgA, IgG or in some instances a polysaccharide(s) or 
glycoprotein(s).59 The abnormally large complex, 150,000 to 2,000,000 Da,60 is 
unable to be excreted in the urine even when there is no renal dysfunction. This 
results in an elevated serum amylase levels.60,61 It is clinically important since it 
appears to indicate a pancreatitis when there is none.
(8) Childhood etiologies
Etiologies of childhood pancreatitis are different than those of adults. Ziegler 
stated that the most common causes of this disease in children were biliary tract 
disease, trauma and congenital abnormalities, which frequently required surgery. 
Biliary tract disease accounted for 33% of the pancreatitis cases, half of these were 
related to a hematological disease, usually sickle cell. Of equal cause (33%) was 
trauma with one third the result of child abuse. Other causes of childhood pancreatitis
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were: systemic disease, congenital abnormalities, and idiopathic.32 Other studies 
showed similar etiologies to adults along with the category of drug induced 
pancreatitis. However, there is disagreement as to the prevalence of various causes. In 
Tagge’s study over an eleven year period involving 33 children, pancreatic causes 
were diagnosed as: ductal abnormalities being the most common, with 12 cases; 
trauma, 10; idiopathic, 4; gallstones, 3; drug induced, 3; and tumor, l.35
A study of 61 children with acute pancreatitis showed that one third of the 
cases were due to multisystem disease (Reye syndrome, sepsis, shock, 
hemolytic-uremic syndrome, viral infections). Also as causes were blunt trauma, 
structural defects, metabolic disease and drug toxicity, and idiopathic.33
A study over a 28 year period involving 48 children with pancreatitis showed 
the following etiologies: 16 were idiopathic; 12 were drug induced, all of which were 
the result of corticosteroid use; 9 were the result of blunt trauma; 7 had obstruction of 
the pancreaticobiliary duct system; two were associated with sepsis; and two had 
recurrent hereditary pancreatitis.34
(9) Other
Certain drugs are well known to elevate serum amylase levels. Morphine 
raises amylase values up to three times normal because opiates constrict the sphincter 
of Oddi, which causes back pressure into the pancreatic duct. Other drugs known to 
cause an increase in amylase levels are choline, methacholine, chlorothiazide, 
pancreozymin, and secretin.20
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Total body irradiation has resulted in increased serum amylase, most of which 
was due to s-amylase, with only 27% due to p-amylase.24
Of a more unusual nature vitamin D intoxication has been validated as a cause 
of recurrent pancreatitis. A patient was admitted four times with acute pancreatitis and 
had serum calcium levels between 13.5 and 14.5 mg/dL. Questioning of the patient 
revealed the intake of excessive quantities of vitamin D. When the vitamin D intake 
ceased, the pancreatitis did not reoccur.62
There still remain some cases of hyperamylasemia that cannot be explained. 
Warshaw investigated 117 patients whose amylase values remained elevated from 
three to forty-eight weeks. Extensive investigation failed to show any reason for the 
persistent elevation. Non pancreatic causes of their hyperamylasemia were attributed 
to 79% of the cases as ascertained by polyacrylamide gel electrophoresis. 
Macroamylasemia was the cause of 6%. Normal distribution of the isoenzymes were 
found in 64% of the patients although they were high. Salivary amylase was elevated 
in 9%63
b. Hypoamylasemia
Normal amylase values can occur even in patients with acute pancreatitis.
They can be related to 1) prevalence of alcoholic etiology, 2) a number of previous 
alcoholic pancreatitis incidents, and/or 3) a duration of symptoms greater than two 
days. Lipase values were elevated in 68% of this group. Acute pancreatitis in patients 
with normal amylasemia is treated the same as those with an elevated amylase 
levels.64 There has also been reported acute pancreatitis with low to normal amylase
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values when there is a pancreatic isoamylase deficiency. The acute pancreatitis was 
confirmed surgically; however, the trypsin was elevated.65 Also low p-amylase values 
have been reported in chronic exocrine pancreatic disease, such as chronic 
pancreatitis, carcinoma of the pancreas, cystic fibrosis, and of rarer occurrence, a 
congenital deficiency.66
4. Test for pancreatitis
a. Amylase
(1) Total
There are three main methods for determining amylase activity. First, 
amyloclastic, in which the free substrate, usually starch, is measured. Second, 
saccharogenic, in which the products (reducing sugars), are measured. Last 
chromolytic, in which the substrate is composed of amylose or amylopectin 
conjugated to a dye at C-2, and the resulting water soluble product (dye-glucoside) is 
measured.12 Currently most commercially used tests for amylase employ the 
measurement of the change in NADH absorbance at 280 nm or of the p-nitrophenol 
released from a maltotetrose substrate. Other substrates that have been investigated 
include: ethylidene-blocked 4-nitrophenyl-maltoheptaoside (EPS), where the 
absorbance of 4-nitrophenol that is released is measured.67 Also, o-(4,6-o- 
isopropylidene-a-D-glucopyranosyl)-( l-»4)-[o-a- D-glucopyranosyl-( l-*4])-5-o-a-D- 
glucopyranosyl-(l-*2)-a-D-fructofuranoside (IPG7F) has been used with the 
subsequent determination of the oxidation rate of NADH.68 Likewise, 2-chloro-4- 
nitrophenyl-a-maltotrioside can be used as a substrate, with the release and
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measurement of 2-chloro-4-nitrophenol.69 These only determine total amylase, i.e. 
they are nonspecific for p-amylase and often necessitate other tests to be performed 
such as serum lipase.
Amylase has come under much scrutiny as to being the best indicator of 
pancreatic disease. The usual indications for acute pancreatitis are abdominal pain and 
a serum amylase levels three times the upper normal limit. Levels less than this value 
are usually due to conditions other than acute pancreatitis.14 Lin suggested from his 
studies that amylase values were diagnostic if  the cutoff was three or four times the 
upper limit, and at this level amylase determination was similar in sensitivity and 
specificity to p-amylase and lipase determinations.70 Diagnostic accuracy of serum 
amylase, p-amylase, lipase, trypsinogen and elastase-1 were: 96%, 96%, 93%, 91%, 
and 84% respectively in 100 patients admitted as emergencies to the surgical 
department and 27 proven acute pancreatitis patients in the study .7I Gwozdz likewise 
found that on hospital admission all serum assays were equally sensitive; however, on 
later tests, lipase, trypsinogen and elastase-1 were more sensitive than serum amylase. 
The Cm/Ccr was found not to be differential.72
There appears to be a growing consensus that amylase values are not as 
elevated in alcoholic causes as in other causes, particularly in biliary tract disease, 
and that amylase values decrease more rapidly in time than some of the other serum 
enzyme tests. The sensitivity of serum amylase, using greater than 1000 U/L, was 
evaluated in 417 patients with acute pancreatitis; 62% were a result of gall stones,
25% from alcohol, 13% of unknown cause. On admission amylase was diagnostic,
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using greater than 1000 U/L, in identifying 96% of the mild cases and 87% of the 
severe. At 48 hrs this was reduced to 33% and 48%, respectively.73 Hiatt found in his 
study that hyperamylasemia due to biliary tract disease was higher, decreased more 
rapidly and to a lower value than hyperamylasemia due to alcoholic pancreatitis.74 The 
occurrence of normal amylase levels in acute pancreatitis can be related to 1) 
prevalence of alcoholic etiology, 2) a number of previous alcoholic pancreatitis 
incidents, and/or 3) a duration of symptoms greater than two days. Lipase values 
were elevated in 68% of this group. Analysis of peritoneal fluid did not increase the 
diagnostic sensitivity. However, bloody ascites and elevated amylase was helpful in 
determining the presence of necrosis and hemorrhage.75
There does not appear to be a correlation between amylase levels and 
pancreatic involvement as seen by computed tomography.26
(2) Isoenzymes
Pancreatic and salivary amylase can be separated by the removal of s-amylase 
by a monoclonal antibody;76-77 wheat germ, which does not completely inhibit salivary 
and does inhibit pancreatic to some extent;76 ion-exchange chromatography;78 or 
electrophoresis.78 These methods are time consuming and lack either specificity or 
quantification. However, the need to differentiate p-amylase from s-amylase remains, 
and the presence of the P3 isoenzyme appears to be significant in the diagnosis of 
acute pancreatitis.
Pancreatic amylase appears to be more sensitive than total amylase in the 
diagnosis of acute pancreatitis, and P3 is even more specific for acute pancreatitis.
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Low p-amylase is significant in exocrine pancreatic insufficiency. Also, a reduced p- 
amylase is suggestive of chronic pancreatitis.79 In pancreatic versus biliary disease, P3 
was found to be the best determinate.80 Isoamylases measured by wheat inhibition and 
cellulose acetate membrane electrophoresis revealed that increased p-amylase is 
indicative of acute pancreatitis, and P3 isoamylase only occurs in acute pancreatitis. 
Positive P3 by cellulose acetate electrophoresis has a positive efficiency of 93% and a 
negative efficiency of 100%. Thus, the use of a P3 to exclude pancreatitis can 
alleviate expensive radiological procedures.81 Isoelectric focusing also showed an 
additional amylase fraction present in acute pancreatitis or pseudocysts similar to the 
P3 fraction.10
P3 isoamylase has been evaluated in a group of 88 patients as an indicator of 
complications of acute pancreatitis. It was found that 92% of the patients who had 
complications (death, pseudocyst and recurrent pancreatitis) had an increase in P3 
levels; whereas, in the group of patients who had acute pancreatitis who had no 
complications at time of discharge only 7% had an increase in P3.82
During acute pancreatitis, it was found that the total and p-amylase levels were 
appreciably higher than the upper levels of control. Also s-amylase was either very 
low or not detected during the acute phase. During the recovery phase of the disease 
the enzyme values tended to return to normal.83
Work has been done by several investigators on the inhibition of one of the 
amylase isoenzymes by a monoclonal antibody to allow the determination of the other 
isoenzyme. Steen developed an enzymatic colorimetric assay that utilizes two
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monoclonal antibodies that inhibit s-amylase. It was found that bilirubin did interfere 
significantly with the assay.84 A monoclonal antibody coupled to plastic beads was 
developed by Svens. It extracted p-amylase from the sample. The catalytic activity of 
the s-amylase that was left was determined by its reaction with blocked p-nitrophenyl 
maltoheptaoside as a substrate.85 Another test being investigated utilizing monoclonal 
antibodies is based on the ability of two monoclonal antibodies to inhibit s-amylase 
nearly completely; therefore allowing the measurement of p-amylase by its catalytic 
action on the substrate, 4-nitrophenyl-alpha-D-maltoheptaoside.86 Another method 
employed a monoclonal antibody against s-amylase that was coupled indirectly to 
particles of polyvinylidene fluoride via a polyclonal goat anti-mouse immunoglobulin. 
This was used to remove s-amylase, and the resultant p-amylase was determined.58
(3) Urinary
Urine amylase has come under scrutiny as to its value in the diagnosis of acute 
pancreatitis. It has been suggested by some to be abandoned. In evaluating urine 
levels [of amylase expressed as activity per volume (U/L) and activity per time 
excreted (U/h) and of amylase/creatinine clearance ratio] and serum levels (of 
amylase, elastase, lipase, and trypsinogen) at admission and repeatedly during 
hospitalization, individual serum assays have the highest sensitivity and specificity.87
b. Other tests
(1) Lipase
The diagnosis of acute pancreatitis is most typically based on the clinical 
picture and elevated serum amylase. Total amylase determination has the advantage of
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availability, technically simple, and at 24 hours of onset of pain as sensitive as lipase, 
pancreatic isoamylase, immunoreactive trypsin or elastase. However, after 24 hours it 
becomes one of the least sensitive. Lipase has the advantage of being more specific 
and almost as sensitive as amylase.88 Of interest the pancreas has four and a half 
times more lipase than amylase.15 The other tests (pancreatic isoamylase, 
immunoreactive trypsin and elastase) are not readily available to most hospital 
laboratories. These tests are best used in cases of difficult diagnosis. Other diagnostic 
procedures, such as ultrasonography, which aids in determining the extent of 
involvement of the biliary tract in the pancreatitis; and computed tomography 
(CECT), which is used in evaluating the extent of pancreatic necrosis, are helpful in 
determining the course of treatment.88 Early operation is suggested in severe acute 
pancreatitis.75
In hyperamylasemic patients with the possibility of acute pancreatitis, serum 
lipase levels remain higher longer than either the pancreatic or total amylase. On 
hospital admission of acute pancreatitis patients, there is a poor correlation between 
lipase and serum amylase. Apple found that the efficiency of p-amylase, lipase, and 
total serum amylase was 94.1%, 76.5%. and 64.7%, respectively.15 Of p-amylase, 
lipase, total serum amylase, urine amylase, and serum amylase, Parodi reported that 
the best indicators for acute pancreatitis were p-amylase and lipase, with 96% and 
95% accuracy.89 Pancreatic lipase appears to have the same temporal sequence as P3; 
however, at present, lipase is more convenient (more available and shorter turn 
around time).90
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The lipase levels are greater in alcoholic pancreatitis as compared to gall 
stone pancreatitis; whereas, in gallstone pancreatitis the amylase levels tend to be 
higher.91 It was found that the lipase values of proven pancreatitis ranged from 1011 
to 25,706 U/L; whereas, in a group of 202 asymptomatic alcoholics the range was 
from 34 to 600 U/L.92 The ratio of lipase to amylase expressed in multiples of the 
upper normal limit of both indicated that a ratio of 2 or greater was indicative of 
alcoholic pancreatitis, and less than 2 implied a nonalcoholic etiology.91 Gumaste 
concluded that lipase was a better determinant for diagnosing acute alcoholic 
pancreatitis than amylase.92
There have been reported some negative aspects of lipase testing. Tereault 
reported some surprising results of lipase values with the Ektachem 700 analyzer. 
Amylase has been reported to be more sensitive; while lipase has been reported to be 
more specific for pancreatitis. Out of 493 patients who had both tests ordered, it was 
found that 103 had values greater than the upper reference limit. Within this group 
lipase had 100% sensitivity and 84% specificity; while amylase had 72% sensitivity 
and 88% specificity.93 In rare cases, elevated serum lipase levels have been reportedly 
due to macrolipasemia.94
(2) Pancreatic phospholipase A2 
Pancreatic phospholipase A2 (PLA2) has been evaluated as an indicator of acute 
pancreatitis since it is released from injured pancreatic acinar cells.95 PLA2 was 
increased in 60% of the chronic pancreatitis patients, 67% of pancreatic cancer 
patients, and 27% of non-pancreatic disease patients (most often in renal failure
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patients).96 However, although present in acute pancreatitis, the pancreas is not the 
only source of PLA2.95 PLA2 levels showed no correlation with lipase or amylase but 
was related to the prognosis of acute pancreatitis. Elevated values have been seen with 
necrotizing pancreatitis and septicemia. Normal phospholipase A2 values were seen in 
uncomplicated acute pancreatitis.97
(3) Immunoreactive trypsin
Trypsin-a 1-proteinase inhibitor (alpha 1PI) complexes and trypsinogen 
comprise immunoreactive trypsin.98 Immunoreactive trypsin (IRT) was shown to 
minimally correlate with serum amylase in patients with acute pancreatitis; however, 
in patients who had persistent IRT with amylase values that had returned to normal, 
there were pancreatic complications, pseudocyst, and hemorrhagic pancreatitis. IRT 
may be useful as a prognostic tool.99 Lankisch summarized that the patient’s recovery 
pattern was best reflected by total amylase and p-amylase levels, and that trypsin in 
cases of delayed diagnosis was a good indicator.100 However, trypsin-a 1PI complexes 
can be elevated in conditions other than acute pancreatitis.98
(4) Acute phase proteins
Certain acute phase proteins tests revealed that a-1-antitrypsin was the most 
sensitive index to diagnose chronic pancreatic disease, and C-reactive protein (CRP) 
reflected the stage of the disease best. These were independent of each other.
However, all of the acute phase proteins (C-reactive protein, ceruloplasmin and alpha- 
1-antitrypsin) were all influenced by liver damage.101 Out of CT, CRP, PLA2, and
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amylase; CT and CRP were determined to be the best indicators of the prognosis of 
acute pancreatitis.102
(5) Miscellaneous
Other diagnostic enzymes currently being investigated for their use in the 
diagnosis of pancreatitis are carboxylic ester hydrolase and elastase 1. Carboxylic 
ester hydrolase can be present in acute pancreatitis without an elevated amylase.103 It 
was also found that carboxylic ester hydrolase remained elevated in necrotizing 
pancreatitis for 10 days but decreased in acute interstitial pancreatitis. Amylase values 
in acute interstitial pancreatitis were higher than in those of necrotizing pancreatitis.104 
Serum elastase 1 sensitivity was superior to lipase, p-amylase and immunoreactive 
trypsin when the cutoff was two times the upper limit; however, its specificity was 
less than lipase or p-amylase. In cases of renal insufficiency, it correlated with 
amylase and p-amylase.105 Serum elastase is reported to be increased to a greater 
extent than serum amylase in acute pancreatitis, and it remained elevated longer than 
amylase.106,107 Serum elastase-1, amylase, lipase, and trypsin-like immunoreactivity 
were all elevated at 24 hours in acute pancreatitis patients. However at 10 days only 
serum elastase-1 and trypsin remained elevated in 90% of the acute pancreatitis 
patients.108 Ventrucci found amylase, pancreatic isoamylase, lipase, trypsinogen, and 
elastase 1 were all elevated on the first day of clinical symptoms. The greatest 
increase was seen in p-amylase; the lowest with elastase 1. With time, all serum 
enzyme levels decreased in a similar fashion except for the elastase 1, which 
remained elevated in all patients longer than the rest.109
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Serum enzyme values (amylase, pancreatic isoamylase, lipase, trypsinogen, 
and elastase 1) vary greatly in chronic pancreatitis patients during remission, and the 
majority of assays are normal (60%). In 67% of chronic pancreatitis elastase was 
within normal range.106 Likewise in pancreatic cancer highly variable enzyme levels 
are seen. Elastase 1 was the most frequently elevated enzyme (35%) in both groups.110 
Gullo had previously found similar findings in chronic pancreatitis and carcinoma of 
the pancreas.107
The most common symptom in acute pancreatitis is severe abdominal pain. In 
evaluating the severity of and determining the etiology, ultrasonography and computed 
tomography are useful and aid in deciding the treatment. ERCP is the most sensitive 
for diagnosing biliary lithiasis. Pancreatic necrosis has also been detected by C- 
reactive protein, PMN-elastase, and trypsinogen activation peptides.111
c. Developmental tests
(1) Radioimmunoassays
Some of the first uses of monoclonal antibodies in diagnostic testing utilized 
radioactive isotopes. These methods were specific and sensitive; however, they have 
lost their importance in the clinical laboratory due to the storage and waste 
management of the radioactive materials. The structural differences between s- 
amylase and p-amylase are small but significant enough that they should enable a 
monoclonal antibody to be produced to each.112 A method by Fujita employing a 
monoclonal antibody to p-amylase has been developed utilizing a radioimmunoassay
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
24
which shows negligible cross-reactivity to s-amylase. His test detects levels as low as 
7 mg/L.113
(2) Enzyme immunoassays
The problem of waste management and storage of radioactive isotopes has led 
the way for the development of a second generation of diagnostic tests that employ 
monoclonal antibodies. A variety of tests that employ monoclonal antibodies are now 
under investigation. Panozzo expressed apprehension in the use of a monoclonal 
antibody for diagnosing chronic pancreatic disease. He stated that the monoclonal 
under his investigation had limitations in its specificity although it was sensitive to 
pancreatic inflammation.114
These tests belong to the group commonly called enzyme immunoassay (EIA). 
There are two main types of EIA: homogeneous, also called enzyme multiplied 
immunoassay technique (EMIT), and heterogeneous, also called enzyme linked 
immunosorbent assay (ELISA). In the EMIT, the antibody is added to the patient 
sample. The enzyme labeled antigen is then added. The sample competes with an 
enzyme labeled antigen for the antibody. If the antibody combines with the enzyme 
labeled antigen, the enzyme reaction is inhibited by the antibody either physically or 
by changing the conformation of the enzyme; thus the more antigen in the sample, the 
more enzyme labeled antigen that can react, which results in an increase in 
absorbance. The resultant color is directly proportional to the amount of antigen in the 
sample. Since there is no phase separation, the assays can be automated and quickly
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performed. There is the disadvantage of interference from other constituents in the 
sample since there is no phase separation. This method is diagramed in Figure 1.
The ELISA requires phase separation of the antigen-antibody complex and the 
unbound constituents. There are two types of ELISA: the competitive, in which the 
resultant color is inversely related to the amount of antigen in the sample, and non­
competitive, also called the sandwich assay, in which the resultant color is directly 
proportional to the amount of antigen in the sample. In the competitive assay the 
antibody is coated on the microwell. The sample with the antigen and an enzyme- 
conjugated antigen are added. The competition of the two antigens results in the 
amount of enzyme that is bound being inversely proportional to the amount of the 
antigen in the sample. The excess constituents are washed off, a substrate is added, 
and the resultant product is determined by a colored assay. This method is shown in 
Figure 2.
In the sandwich assay, there are two binding sites to the antigen. Again the 
well can be coated first with an antibody. The sample with the antigen is added, the 
unbound constituents washed off, and an enzyme-conjugated antibody (a second 
antibody) that is specific for a different epitope of the antigen is added. The excess is 
washed off, and again the substrate is added that results in a colored product being 
formed. The resultant color is directly proportional to the amount of the antigen 
present. Figure 3 demonstrates this reaction.
A number of researchers have produced pairs of monoclonal antibodies for 
either p-amylase or s-amylase. Diamandis determined p-amylase levels by the use of
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Figure 1
Principle of the homogeneous enzyme immunoassay










































































Principle of the competitive heterogeneous enzyme immunoassay
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Figure 3
Principle of the sandwich heterogeneous enzyme immunoassay
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two monoclonal antibodies. One was immobilized to a microtiter well; the other was 
biotintylated. By the addition of streptavidin which was labeled with an europium 
chelator, the resulting fluorescence was measured, and the immunocomplex 
quantitated. The antibodies used showed low cross reactivity with s-amylase.115 
Fujisawa also has reported success in using two monoclonal antibodies specific for p- 
amylase. This work also showed little cross reactivity to s-amylase.116 Another 
enzyme immunoassay that employed two monoclonal antibodies for detecting p- 
amylase, the latter being conjugated with peroxidase, was investigated by Fujisawa.116 
Rosenblum has produced two monoclonal antibodies that bind p-amylase and do not 
block the active site of the enzyme. Good correlation with isoamylase determination 
by electrophoresis was obtained.117
A test strip that is composed of monoclonal antibodies to s-amylase has been 
produced by Lorentz. It has been demonstrated to be useful in cases of slightly 
elevated amylase levels.118 
B. Objectives
The purpose of this research was to develop a solid phase enzyme 
immunoassay for determining p-amylase and s-amylase. This method involves the 
immobilization of cycloheptaamylose to the microwell. Subsequently, the p- 
amylase and s-amylase in the sample bind to the inhibitor. The respective levels of 
p-amylase and s-amylase are determined by the reaction of the specific monoclonal 
antibody against p-amylase or s-amylase. The prevalence of p-amylase and s-
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amylase in hyperamylasemic patients were determined. The order of development
and specific objectives were as follows:
1. Isolation and purification of p-amylase and s-amylase.
2. Production of monoclonal antibodies against the purified p-amylase and
s-amylase by hybridoma technique.
3. Purification and characterization of the monoclonal antibodies.
4. Employment of the purified monoclonal antibodies for development of a
solid phase enzyme immunoassay (EIA) for serum amylase.
5. Characterization of the developed solid phase EIA method and comparison 
with electrophoresis for determination of p-amylase and s-amylase in 
hyperamylasemic patients.
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Chapter I I  
EXPERIMENTAL
A. MATERIALS:
All chemicals were Reagent Grade unless otherwise stated.
AAPER Alcohol and Chemical Co.: ethanol (USP)
Aldrich: 1,4 butanedioldiglycidyl ether 
Allied Chemical: dibasic sodium phosphate
American Type Culture Collection: NS1 (non-secreting mouse myeloma) 
cells
Becton Dickson: 1 cc and 3 cc syringes; 30 G, 25 G, 22 G, 18 G 
Corning: 24 microwell plate
Dynatech Laboratories, Inc.: Immulon 1 Removawell strips 
E.M. Science: ethyl ether anhydrous, sulfuric acid 
Ethicon: ethicon silk 4.0
Falcon: 25 cm2 50 mL culture flask, 10 x 35 mm tissue culture dish;
15 mL sterile centrifuge tube 
Fisher: sodium meta periodate, sodium acetate, sodium hydroxide, 
dextrose, citric acid monohydrate, glycerin, boric acid 
Gelman Instrument Company: Cellulose electrophoresis strips 
(Super Seprapore)
31
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Gibco: Iscove’s medium (IMDM), Fetal bovine serum (FBS);
penicillin/streptomycin (lOOx); Hybridoma-Serum Free Media 
JRH Biosciences: HAT selective supplement (lOOx)
J. T. Baker Chem Co.: Iodine, sodium borohydride, cyclohexane 
Jackson Laboratories: BALB/CByJ mice 
Kai: Miltex Stainless steel sterile surgical blade 
Mallinckrodt: sodium chloride, methanol, ammonium chloride 
Millipore: 0.22 nm filter unit with filling bell 
Monoject, Division of Sherwood Medical: heparinized capillary tubes 
Nunclon: 96 microwell plate 
Oxford Labware: critoseal 
Pharmacia Diagnostics: Phadebas Amylase test tablet 
Sigma: salivary a amylase, sodium phosphate (monobasic anhydrous), 
Trizma Base (Tris [hydroxymethyljaminomethane), 
cycloheptaamylose (CHA, (3 cyclodextrin), Sepharose 6B, 
phenylmethylsulfonyl fluoride, j8 glycerophosphate, amylose, 
3,3’ ,5,5’-tetramethylbenzidine (TMB); Goat anti-Mouse IgG (whole 
molecule) Peroxidase Conjugate; Polyethylene glycol 
(PEG);lipopolysaccharide (LPS); sodium bicarbonate; Ovalbumin 
(OVA); polyoxyethylene-sorbitan monolaurate (Tween 20); HT 
media supplement:hypoxanthine 5 x 10'3 M thymidine 8 x 10"4 M,
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50 X (HT); RPMI 1640 medium, with L-glutamine, without sodium 
bicarbonate;sodium azide, horse serum albumin, Protein A on 
Sepharose 4B fast flow, N-hydroxysuccinimide (NHS),
1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
urea-hydrogen peroxide, barbital buffer, Sigma ImmunoType Mouse 
Monoclonal Antibody Isotyping Kit 
Spectrum Medical Industries, Inc.: Spectra/Por dialyzing tubing 23 mm x 
100 ft, m.w. cut off 6,000-8,000; and 10 mm x 50 ft, m.w. cut off 
12,000-14,000
Voluntary Hospitals of America Supply Company: VHA Level I and 
VHA Level D (normal and abnormal human serum controls)
B. EQUIPMENT
Amicon Filtration System, model 12 and 52 with a YM10 filter 
Beckman Appraise Densitometer
Beckman Microzone Cell Model R-101 Electrophoresis chamber 
Beckman Model CDS-200 Computing Densitometer Scanner 
Beckman Model TJ-6 centrifuge
Beckman sample applicator for cellulose acetate electrophoresis 
Bio-Tek Instruments Model 207 Microplate reader 
ISCO Model UA-5 Absorbance/Fluorescence Monitor 
Nicolet 5PC FT-IR Spectrometer
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Rotomix Type 48200 by Thermolyne Sybron 
Warring Commercial Blender
C. Methods
1. Preparation of antigens 
a. Pancreatic amylase
(1) Extraction
The visible fat was trimmed from a normal human pancreas obtained from 
autopsy; the pancreas was then weighed. A buffer (containing 320 mg 
phenylmethylsulfonyl fluoride, 50 mM of /3-glycerophosphate, and 150 mM of 
NaCl, pH 7.0) was added to the pancreas in a volume of 5:1 was placed in a 
Warring blender with the pancreas. The pancreas was homogenized with the buffer 
for 60 s. The resulting mixture was centrifuged at 4°C for 30 min at 5000 g. The 
fat rose to the top while the other debris remained at the bottom. The liquid 
portion was poured through four layers of gauze to retain the fatty material.
(2) Purification
(a) Production of cycloheptaamylose Sepharose-6B 
A sufficient quantity of Sepharose 6B was washed and dried on a course 
glass filter funnel with water to yield 20 grams. Twenty mL of 0.6 M NaOH 
containing 2 mg/mL sodium borohydride was added, followed by the addition of 
20 mL of 1,4-butanediol diglycidyl ether. The mixture was divided evenly between 
two 50 mL plastic centrifuge tubes. These were mixed on a platform rocker for 8
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h at 25°C. The mixture was poured onto a course glass filter funnel and washed 
with 4 L of deionized H20 119. A schematic of the reaction is shown in Figure 4.
Twenty grams of the freshly prepared epoxy-activated Sepharose 6B that 
had been dried on a glass filter funnel was combined with 1500 mg of 
cycloheptaamylose and 60 mL of 0.1 M NaOH in two 250 mL Erlenmeyer flasks. 
The flasks were put on a shaker in a 45 °C water bath for 19.5 hr. After 
incubation, the coupled Sepharose was washed for 30 min with approximately 4 L 
of deionized water on a glass filter funnel with slight aspiration. It was then 
washed with dextrose (25 mg/mL, approximately 500 mL) for 30 min with no 
aspiration. It was washed again with approximately 4 L of deionized water for 30 
min with aspiration. It was finally washed with 4 L of 50 mM sodium acetate 
buffer pH 4.8 for 2 hr with no aspiration.120121 The final reaction is shown in 
Figure 5.
(b) Affinity chromatography
Equal portions (70 mL of each) of the above liquid portion (p-amylase 
homogenate) were mixed with a 50% solution of CHA-Sepharose in equilibration 
buffer (50 mM sodium phosphate and 50 mM of NaCl, pH 6.9) for 10 min in a 20 
x 5 cm column. The column was then connected to a ISCO Model UA-5 
Absorbance/ Fluorescence Monitor with the wavelength set at 280 nm. A sample 
of the eluent was tested to determine if any amylase was still present. One hundred 
/xL of the sample were added to 100 /xL of working substrate solution and
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Figure 4
Activation of Sepharose with 1,4-butanediol diglycidyl ether
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Figure 5
Reaction of coupling CHA to sepharose
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incubated at 37 °C for 20 min. Then 850 /xL of working iodine solution were 
added. Negative results for amylase appeared blue purple in color; whereas, 
positives appeared brown to dark yellow. The eluent was saved if  it tested positive 
for amylase, and the extraction was repeated with reequilibrated CHA-Sepharose 
till no amylase was left in the eluent. The CHA-Sepharose-amylase was washed 
with the equilibration buffer till the base-line was stable. The amylase was eluted 
with 8.0 g/L of CHA in equilibration buffer. The eluent was monitored at 280 nm, 
and the eluent corresponding to the recorder peak was collected. The gel was 
reequilibrated by removing it from the column, placing it in a glass filter funnel, 
then washing it with the equilibration buffer (approx 100 mL). Next, it was 
washed with 1 N NaCl (approx 75 mL). Finally, it was washed and re-equilibrated 
with equilibration buffer (approximately 150 mL). The p-amylase was dialyzed in 
6 L 10 mM PBS, pH 7.4, overnight with 2 changes of buffer to remove the CHA. 
All of the eluents were concentrated with an Amicon Ultrafiltration System, model 
12 and 52 equipped with a YM10 filter. The concentrated p-amylase was stored in 
1 mL aliquots at -80°C m.
b. Salivary amylase 
The s-amylase was purchased from Sigma. The solid (19 mg, 2500 units, 
1450 units/mg protein) contained 1.724 mg protein and was reconstituted with 10 
mL of 1 mM CaCl2. The amylase was dialyzed with 6 L of 10 mM PBS, pH 7.4,
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to remove the (NH4)2S04 in which it was stored. The buffer was changed 2 times 
every 8 hours. The s-amylase was frozen in 1 mL aliquots at -80°C.
2. Production of antibodies
a. Immunization of mice 
A 5 week old BALB/CByJ male mouse was anesthetized by an 
intraperitoneal injection of pentobarbital (40-70 mg/Kg body weight). The animal 
was placed on its right side, and the area exposed on the left side of the abdomen 
was washed with 70% ethanol. A 0.5-1.0 cm incision was made aseptically into 
the left abdomen below the rib with small sterile scissors, exposing the spleen but 
not cutting through the peritoneum. Into the spleen, 100 nL of the p-amylase, 
which was diluted with 10 mM PBS, pH 7.4, to a concentration of 400 /xg/mL (40 
fig) were injected with a 1 mL syringe, 1/2 in 30 G needle. Using ethicon silk 4.0, 
two stitches were made aseptically to close the skin. The first booster of 20 fiL  of 
p-amylase, which was diluted with 10 mM PBS, pH 7.4, to a concentration of 2 
mg/mL (40 fig) was given 11 days after initial injection using a 30 G needle via 
the tail vein. A second booster was given 13 days after the initial injection in the 
same manner as the first booster. The procedure was repeated with another mouse 
using s-amylase as the antigen.
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b. Titer determinations
(1) Antigen well preparation
The Immulon 1 microtiter wells were coated with 200 L of p-amylase at a 
concentration of 1 jttg/mL, in a coating solution. After an incubation of a minimum 
of five hours (or overnight), the wells were washed 7 times with 10 mM PBS, pH
7.4, with 0.1 % Tween followed by 7 times with deionized water. The wells were 
air-dried for approximately 10 min. Blocking of non specific binding was 
performed with a 0.3 % OVA in coating solution, 200 piL/well. After incubation 
for 2 hours, the wells were again washed 7 times with 10 mM PBS, pH 7.4, with
0.1 % Tween, followed by 7 times with deionized water and air dried for 
approximately 10 min. The procedure was repeated using s-amylase as the antigen 
with another set of wells.
(2) Titer assay
A serum titer assay was performed to determine if  sufficient antibodies 
were produced from the immunizations by the following procedure. A small 
incision was made in the tail of the mouse with a sterile stainless steel surgical 
blade, and a heparinized capillary tube was used to collect blood. The tube was 
filled approximately 2/3, then the end of the tube was sealed with critoseal and 
centrifuged at 1000 g for 10 min. Five /xL of plasma was removed and serially 
diluted with 10 mM PBS, pH 7.4. Dilutions were 1:200; 1:400; 1:800; 1:1600; 
1:3200; 1:6400; 1:12800; 1: 25600; 1:51200; 1:102400; and 1:204800. To the
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antigen-coated wells, 200 /xL of each dilution were added and incubated at room 
temperature for at least 2 hours. Again they were washed 7 times with 10 mM 
PBS, pH 7.4, with 0.1 % Tween, followed by 7 times with deionized water and air 
dried for approximately 10 min. Goat-anti-mouse IgG-HRPO, 200 ptL/well, were 
added at a concentration of 5 /xL diluted to 25 mL (1:5000) with 10 mM PBS, pH
7.4. The wells were incubated at room temperature for 1 hr. The wells were 
washed 7 times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times 
with deionized water and air dried for approximately 10 min. To the wells, 100 
nL of buffered peroxide solution were added followed by 100 /xL 3, 3’ , 5, 5’- 
tetramethylbenzidine (TMB) solution. The wells were mixed on a rotator till a blue 
color appeared. The reaction was stopped with 50 /xL of 2 N H2S04. The wells 
were then read on a microplate reader at 450 nm, and the titer determined.
I f  the titer was not at least a hundredfold increase from the base line, the 
mouse was boosted in a similar manner every 2-3 weeks. A significant titer was 
expected to be at least a hundredfold difference of undiluted serum. If  the titer was 
significant, the animal was sacrificed 1-3 days after the final boost. The spleen 
cells were harvested for cell fusion.
The same procedure was used utilizing s-amylase as the antigen in a second 
5 week old BALB/CByJ male mouse.123
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c. Cell fusions
A ll dissection tools were sterilized in a hot oven (100°C) overnight. The 
day of the fusion, 70% ethanol was added to the dissection tray prior to use. The 
following were put in a 37°C water bath: MC-IMDM (25 mL), Serum Free 
Medium (40 mL), FBS (10 mL), LPS solution (0.2 mL of 4 mg LPS/mL of 
IMDM), HAT (50 X) (2.0 mL). A 50% warm PEG solution was prepared by 
autoclaving 1 g PEG for 15 min at 15 psi, then adding 1 mL RPMI 1640 when the 
PEG was warm.
NS-1 cells were grown in complete medium in a 37 °C incubator with 100% 
humidity and 5 % C02 in 50 mL Falcon tissue culture flask to yield 2 x 107 - 5 x 
107 NS-1 cells (1/2 to 1/5 the number of spleen cells for fusion). On the day of 
fusion they were transferred to a 15 mL sterile centrifuge tube and centrifuged at 
100 xg at room temperature for 5 min, and the supernatant was aspirated. They 
were resuspended in 5 mL Serum Free Media.
The mouse was boosted 1-3 days prior to fusion day. (If mouse was 8 
weeks or less of age, the thymus was saved for thymocyte harvesting.) The mouse 
was sacrificed by cervical dislocation, and the abdomen was soaked with 70% 
ethanol. The spleen was carefully removed, using sterile technique. The spleen 
was placed in a 10 x 35 mm culture dish containing Serum Free Media and rinsed. 
It was transferred to another dish and rinsed again. The tissue was gently tom 
apart with forceps, minced with scissors, then mixed with the use of a 1-mL
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plastic syringe. The spleen cell suspension was transferred through a sterile wire 
sieve, rubbing the tissue against the sieve, into a sterile 15 mL sterile centrifuge 
tube. A sample was taken and counted to determine the number of spleen cells.
For fusion 1.0 x 10 8 spleen cells were needed. The suspension was centrifuged at 
100 xg for 5 min at room temperature, and the supemate was removed by suction. 
To dissolve the erythrocytes that were present, 5 mL 0.85% NH4C1 solution were 
added to tube and allowed to stand at room temperature for 5 min. The solution 
was centrifuged as before, and the supernatant aspirated. The pellet was 
resuspended in 5 mL Serum Free Media.
Thymocytes were obtained from a BALB/CByJ 5 weeks old mouse. 
(Thymocytes from the boosted mouse were used if  under 8 weeks of age.) The 
mouse was sacrificed by cervical dislocation. The chest and throat area were 
sterilized by washing with 70% ethanol. The chest cavity was opened by standard 
procedure, and the thymus removed. It was rinsed with 3 mL Serum Free Media 
in a 10 x 35 mm tissue culture dish to remove as much blood as possible. It was 
transferred to a second dish and rinsed again. In a third culture dish, the gland was 
carefully tom with forceps to free the thymocytes into the 3 mL of the media. The 
tissue-cell mixture was further mixed with a 1 mL plastic syringe. The cell 
suspension was transferred through a sterile wire sieve, rubbing the thymus tissue 
against the sieve, into a sterile 15 mL tube, and a sample of the cell suspension 
was counted. Sufficient quantity was transferred to a 15 mL sterile tube to yield
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2 X 108 thymocytes. The cell suspension was centrifuged at 100 xg for 5 min at 
room temperature. The supernatant was removed by suction. The cell pellet was 
resuspended in 1.4 mL 2X IMDM. The suspension was combined with 10 mL of 
FBS, 1 mL HAT (100X), and 0.2 mL of LPS solution (4 mg LPS/mL IMDM), 
plus 2.4 mL D.W. [Final volume 15 mL, Solution T]
Cell fusion was accomplished by the following schematic in Figure 6.
d. Hybridoma clone selection
A 96 well plate was prepared by adding 250 /xL of complete medium that 
contained 1 x 104 to 105 thymocytes in each well. After approximately 10 days 
incubation after cell fusion, clones were selected that were smooth and 
homogeneous, had one center with well defined edges, and were not closer than 
1.5 mm. The size of clone was between 0.5 mm and 1 mm. Using a dissecting 
scope in a closed plastic hood, each clone was siphoned with 50 /xL pipette and 
dispersed one clone per well into the aforementioned 96 well plate. The clones 
were fed 1 drop (25 jtxL) of 1 x 104 to 105 thymocytes per well once a week, two 
times.124
e. Hybridoma clone propagation
When the media turned yellow, indicating good cell growth, the well was 
mixed and 150 /jlL  were transferred into one well of a 24 well plate containing 1 
mL of complete medium with 1 x 104 thymocytes. The 150 /xL were replaced with
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Figure 6 
Cell fusion schematic
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new complete medium with thymocytes. When a well turned yellow the second 
time, a back up was made in another 96 well plate.
f. Hybridoma clone screening 
Wells coated as previously described with either s-amylase or p-amylase 
were used to screen antibody production by the clones. After 10-14 days of 
growth, 100 /xL of coating solution were pipetted into each well. Then 100 /xL of 
supernatant of each clone well that had a yellow supernatant were added into each 
test well and incubated at room temperature for 2 hours. The wells were washed 7 
times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times with 
deionized water, and dried for 10 min. Goat-anti-mouse IgG-HRPO, 200 /xL/well, 
were added at a concentration of 5 /xL diluted to 25 mL (1:5000) with 10 mM 
PBS, pH 7.4. The reaction was incubated at room temperature for 1 hr, then 
washed 7 times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times 
with deionized water, and finally air-dried for 10 min. To the wells, 100 /xL of a 
buffered peroxide solution and 100 /xL 3, 3’ , 5, 5’-tetramethylbenzidine (TMB) 
solution were added. The plate was mixed on rotator till a blue color appeared.
The reaction was stopped with the addition of 50 /xL of 2 N H2S04. The 
absorbance was read at 450 nm in a microplate reader; zero was set with a goat- 
anti-mouse IgG-HRPO blank.
Clones were selected that had good growth, were highly reactive with their 
respective antigen, and were negative for the opposite antigen. Also, a third group
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was selected that showed good cross reactivity to both antigens. These were 
transferred to 24 well plates, which contained 2 mL/well of complete medium and 
incubated at 37°C in 100% humidity and 5% C02. From each of the above clones, 
hybridoma cells were frozen for back up.
g. Cultivation of antibodies
(1) Production of antibodies in vitro
As the hybridoma cells continued to grow, the supernatant of the culture 
medium turned acidic (yellow in color). At this time 1 mL of the supernatant was 
transferred aseptically to a 50 mL centrifiige tube and stored at -20 °C till sufficient 
volume of supernatant was collected. One mL of complete medium was added to 
replace the supernatant that was removed. Two cell lines, 2PE10 and 2PC2, were 
also grown in Serum Free Hybridoma Media utilizing the same methodology.
(2) Production of antibodies in ascites fluid
An 8 week old BALB/CByJ male mouse was primed with 0.5 mL pristane 
intraperitoneal 3-4 days prior to hybridoma injection. Incomplete Freund’s 
Adjuvant was also injected intraperitoneal as a primer in some of the mice (0.25 
mL, 7-10 days prior to hybridoma injection). The hybridoma cells that were grown 
in complete medium were counted and sufficient quantity was transferred to a 
centrifuge tube to yield 2 mL of 1 - 2 x 107 cells/mL needed for injection. After 
centrifuging, the resultant supernatant was aspirated. Two mL of serum free 
medium was added to the pellet, and the cells were resuspended. The cells were
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drawn into a 3 cc syringe with no needle attached. After the cells were in the 
syringe, a 25 G needle was attached, and the air was removed from the syringe 
and needle bringing the volume to 2 mL. The mouse’s abdomen was washed with 
70% alcohol, and 2.0 mL of 1 - 2 x 107 cells/mL were injected in intraperitoneal.
The mouse was checked for the production of ascites fluid. Beginning at 
one week and as late as three weeks depending on the growth rate of the cell line, 
the mouse would exhibit an extended abdomen. When the abdomen became 
distended, it was washed with 70% ethanol. The peritoneum was punctured with 
an 18 G needle on a 3 cc syringe, and the ascites fluid was collected drop-wise 
into a sterile test tube while applying gentle pressure to the sides of the abdomen 
of the mouse. The aspirate was frozen, and each succeeding tap of ascites fluid 
was frozen till the mouse expired. The procedure was repeated with each 
hybridoma cell line used.125
h. Purification of antibodies 
The cell culture supernatant or ascites fluid was centrifuged for 5-10 min at 
approximately 100 xg, and the supernatant measured. A Protein A-Sepharose 
column was washed with 10 mM PBS, pH 7.4, with the monitor set at 280 nm 
until the baseline was stabilized. The supernatant of the cell culture or ascites fluid 
was applied to the Protein A-Sepharose column. The first peak (1st fraction) 
containing the unwanted protein was discarded. The column was washed with 10 
mM PBS, pH 7.4, until the baseline was again reached and stable. The column
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was then washed with the elution buffer, and the effluent (2nd fraction) was 
collected into a flask. The elution was continued until the base line was again 
reached and was stable. The effluent in the flask was adjusted to pH 7.0 with 1.0 
N NaOH. The effluent, which contained the IgG fraction, was transferred to 
dialyzing tubing then dialyzed twice in 6 L of 10 mM PBS, pH 7.4, for 8 hrs 
each. The dialysate was concentrated with an Amicon ultrafiltration system using a 
YM-10 filter, and the concentrate was stored in 1 mL aliquots at -20°C. The 
Protein-A Sepharose column was washed and stored in 0.02% sodium azide in 10 
mM PBS, pH 7.4, at 4°C.126
i. Conjugation of antibody with horseradish peroxidase (HRPO) 
Sufficient HRPO was dissolved into 0.1 M sodium acetate buffer, pH 4.5, 
to give a final concentration of 10 mg/mL. Equal volumes of the HRPO solution 
and 0.1 M NaI04 were mixed and allowed to react at room temperature for 5 
minutes. The mixture was then dialyzed in 6 L of 10 mM sodium acetate buffer, 
pH 4.0, overnight at 4°C with two changes of the solution. The antibody to be 
labeled with HRPO was put in a 0.1 M carbonate buffer, pH 8.3, to a final a 
concentration of 2 mg/mL. Equal volume of periodate oxidized HRPO and the 
antibody solution were mixed and allowed to stand at room temperature for 4 
hours. The reaction was stopped with a NaBH4 solution (1 mg/mL) in a volume 
ratio of 1:20 to the above reaction mixture. The antibody-HRPO was then dialyzed 
against 6 L of 10 mM PBS, pH 7.4, at 4°C for at least 6 hours. Horse serum
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albumin was added to the sample to a final concentration of 10 mg/mL and 
dialyzed once more in 6 L of 10 mM PBS, pH 7.4, at 4°C for at least 6 hours.
The antibody-HRPO was placed at 4°C for short term and -20°C for long term 
storage.
j. Isotyping of antibodies
Each antibody was tested with Sigma ImmunoType Mouse Monoclonal 
Antibody Isotyping Kit, stock No. ISO-1 according to the manufacturer’s 
procedure. Two mL of antibody in a concentration of 1 jug/mL were used.
3. Assay conditions
a. Well coating studies
(1) CHA preparation studies
Into a 15 x 150 mm test tube, 1.6 g of CHA and 0.16 g of NaN02 were 
placed in an ice water bath. To the CHA and NaN02 mixture, 5 mL of ice cold 
concentrated nitric acid were added. The top of the test tube was sealed with 
parafilm to trap the N02 that was produced. The mixture was maintained at 4°C 
and stirred until all of the solid CHA was dissolved. One mL aliquots of the 
mixture were taken at 8, 12, 24, 36, 42, and 48 hr. To the 1 mL aliquots, 8 mL 
of ether were added to precipitate the CHA. The tube was centrifuged for 5 min at 
100 xg, and the supernatant was removed. The precipitate was washed again with 
4 mL of ether then centrifuged, and the supernatant removed. The precipitate was 
allowed to air dry.127
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Each of the oxidized CHA samples was analyzed by infirared analysis on a 
Nicolet 5PC FT-DR Spectrometer.
(2) CHA:BSA coupling studies 
From the 36 hr oxidized CHA sample, a stock solution of 10 mg/mL 
deionized water was made. The CHA was activated by adding 0.1 M each of EDC 
and NHS in deionized water to 2.4 x 10'3 M of CHA. This was mixed on a rocker 
at room temperature for 30 min. BSA diluted in 0.1 M carbonate buffer, pH 8.6, 
to a concentration of 1.5 x 10-4 M was conjugated to the activated CHA and 
incubated on the rocker for 1 hr at 4°C in 1:1, 1:2, 1:4, and 1:8 ratios. This was 
repeated with increased EDC/NHS in the concentration of 0.1 M of each. This 
reaction is diagramed in Figure 7. The resulting CHA-BSA was dialyzed overnight 
in 6 L of 50 mM Tris buffer pH 8.5 with 2 changes of the buffer.
Tenfold dilutions were made of the CHA-BSA with the coating solution 
starting at 1 mg/mL. Two hundred /xL aliquots were added to each well. The wells 
were incubated overnight at room temperature in a moist chamber.128129
b. Washing studies 
Deionized water; 10 mM PBS, pH 7.4; and 10 mM PBS, pH 7.4, with 
0.1 % Tween (PBS-Tween) were chosen as possible washing solutions. Rinsing 
patterns performed were 3/3, 5/5, 7/7 of each of the washing solutions followed 
by deionized water. Rinses were performed after well coating, blocking, sample 
incubation and antibody incubation. The wells were completely filled with the
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Figure 7
Reaction of coupling CHA to BSA
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rinsing agent, then emptied, and after the final rinse were allowed to air dry in 
front of a fan for 10 min.128
c. Blocking studies
The wells were filled with 300 /*L of blocking agent and incubated in a 
moist chamber. Blocking agents investigated were BSA, OVA, and skim milk in 
coating solution at the following concentrations: 0.3%, 0.5%, 1 %, 3%, and 5%. 
Incubation was performed at room temperature and 37°C for 30, 45, 60, 90, and 
120 min.128
d. Sample studies
(1) Sample diluent study
Samples were diluted with 10 mM PBS, pH 7.4, 10 mM PBS, pH 7.4, with 
8 mmol/L CaCl2, and 10 mM PBS, pH 7.4, with 0.1 % skim milk . Each sample 
was serially diluted twofold with the diluent.128
(2) Sample size study
Two control sera (normal and abnormal) were serially diluted with 10 mM 
PBS, pH 7.4, with 0.1 % skim milk (PBS-SM) and tested with the cross reacting 
2PC12-HRPO antibody.
(3) Sample incubation study
Blanks (PBS-SM) and samples were incubated in a moist chamber at room 
temperature and 37°C for 30, 45, 60, 90, and 120 min.
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e. Antibody-HRPO incubation study
The HRPO-conjugated antibody was diluted with 10 mM PBS, pH 7.4, and 
incubated in a moist chamber at room temperature and 37°C for 30, 45, 60, 90 
and 120 min.
f. Indicator system studies
The substrate solution (solution A) was added proportionally to the well 
coating as established previously in this laboratory. The chromogen solution 
(solution B) was of equal volume to the substrate, and the 2 N H2S04 was half 
volume to the previous two solutions. The color development was allowed to react 
for 5, 10, 15 and 20 min with serial dilutions of p-amylase and 2PC2-HRPO; 
likewise, with the s-amylase and 2S2F7-HRPO.
4. Studies of the performance characteristics of the enzyme
immunoassay
a. Linearity studies
The standards (p-amylase and s-amylase) were added to human serum with 
a predetermined amylase level of less than 10 U/L. Each standard was made with 
the PBS-SM by twofold dilutions starting with a concentration of 1000 U/L of the 
respective isoamylase. These were tested with the appropriate HRPO-antibody.
b. Limit of detection studies
Twenty blanks were tested with 2PC2-HRPO and 2S2F7-HRPO.
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c. Precision studies
Twenty determinations of commercially prepared normal pooled serum 
were determined with 2PC2-HRPO and 2S2F7-HRPG. Twenty assays using 
commercially prepared abnormal pooled serum were also performed with the two 
antibodies.
d. Cross reaction studies
The standards of p-amylase and s-amylase were each tested with the 
reciprocal antibody, p-amylase with 2S2F7-HRPO and s-amylase with 2PC2- 
HRPO.
5. Validation studies of human sera
a. Enzyme immunoassay
Twenty patient samples, normal control, and abnormal control were 
analyzed on Immulon 1 wells previously coated with 20 pg/vjtH CHA:BSA that 
had been blocked with PBS-SM for 45 min at 37°C. The samples were diluted 1:5 
with PBS-SM, and 200 pL were added to each well. These were incubated at 
room temperature for 60 min. They were then washed seven times with 10 mM 
PBS, pH 7.4, with 0.1 % Tween followed by seven times with deionized water.
The samples were incubated for 45 min at 37°C with 200 pL of each of the two 
antibodies, 2PC2-HRPO and 2S2F7-HRPO, that had been diluted to 1:600 and 
1:700 respectively. The wells were again washed, and the two color developing 
solutions, A and B, were added. When a blue color developed, the color reaction
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was stopped with the addition of 2 N H2S04. The resulting yellow color was read 
on the microplate reader at 450 nm.
b. Total amylase
Total amylase determination of the patients samples were performed on a 
Beckman CX7 which measured the amount of NADH produced.
c. Electrophoresis
Gloves were worn to prevent any contamination. The number of 
applications of the sample onto the cellulose acetate strip was the equivalent of one 
application of a sample of an amylase of 500 U/L. This was made about 1.5 cm 
from the cathode end of the plate. Tris and barbital buffers were kept refrigerated 
then put into the anode and cathode chambers respectively. Electrophoresis was 
performed at 3 mA for 1.5 hours with the chamber in an ice bath. After 
electrophoresis, the strip was put into a closed chamber with one drop of water 
between the cellulose acetate and the glass plates to ensure that it lay perfectly flat. 
A Phadebas Amylase test tablet diluted with 3 mL of 8 mmol/L CaCL was poured 
onto the electrophoresis plate and incubated at 40°C for 1.5 hours. After 
incubation, the plate was quickly washed under cold tap water, then put into 
methanol for 5 min to fix the blue bands to the cellulose acetate matrix, and then 
cleared in 30% cyclohexane in absolute ethanol for one min. The plate was dried 
in a warm oven for approximately 3 min. The strip was scanned at 595 nm, and 
the percentages of p-amylase and s-amylase were computed.22130
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Chapter m  
RESULTS
A. Preparation of antigens
Pancreatic amylase is unavailable commercially. A pancreas was 
homogenized and p-amylase was purified by affinity chromatography using CHA- 
Sepharose. The amylase was eluted with a solution of 0.8% CHA. This was later 
removed by dialysis. As seen in Table 1, not all of the amylase was totally 
extracted, still a large amount of p-amylase was obtained with a 58.8% yield from 
the original 100.65 grams of pancreatic tissue.
B. Production of antibodies
1. Immunization of mice
The immunization of the first p-amylase immunized mouse was particularly 
long due to the fact that NS1 cells were not available until the 17th week. Two 
mice were immunized with s-amylase. The hybridoma clone maintained from the 
first s-amylase mouse proved to produce too low of an antibody titer to be useful. 
The second s-amylase immunized mouse was maintained with boosters and was 
later utilized for cell fusion. However, due to a fungal infection, both p-amylase 
and s-amylase cell lines were lost from the fusions of the first p-amylase mouse 
and the second s-amylase mouse. Two more pairs of mice were immunized with p- 
amylase and s-amylase. The second p-amylase mouse gave rise to the cell line that 
was ultimately used for testing. The cell fusion from the third s-amylase mouse
57
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homogcnatc 425 409 @ 100 44100 40900 1803690
0
441
#1 CHA 21 5.5 .338 930 1.9 5115 2692 0.03 6
#2 CHA 54 41 .653 85000 268 3485000 130037 19.3 295
2nd extract 
#2
28 .653 86000 18.3 2408000 131585 13.4 298
#3 CHA 144 50 .22 41500 11 207500 188636 11.5 428
2nd extract 
#3
13.5 .258 42000 3.5 567000 162931 3.1 369
#4 CHA 190 48 .266 43400 12.8 2083200 162750 11.5 369
NOTES:
no 3rd extract performed on §2 and #3
no 2nd extract performed on #4; had enough p-amylase; therefore, did not continue.
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resulted in poor results due to the MC-IMDM having aggregates of media. The 
alternate mouse was boosted and used for cell fusion. The summary of the 
immunizations are shown in Table 2.
2. Titer determinations
All of the mice used exhibited a significant titer at 13 days. The continued 
immunization was due to other factors. The titers of P2 and P3 mouse are shown in 
Figure 8. The P2 mouse gave rise to the cell line used for testing (2PC2). The cells 
from the P3 mouse were never used. The titers of S3 and S4 mice are shown in 
Figure 9; mouse S4 gave rise to cell line 2S2F7 which was used in testing.
3. Cell fusions
The number of clones produced from the six cell fusions varied from 12 to 
468. The ideal number to work with was approximately 100. Greater than this 
number of cells becomes unmanageable to maintain. Clone picking was usually 
performed only once. The one fusion that yielded 468 clones necessitated picking half 
of the clones one day and the remaining plates of clones the second day. Since clones 
that appeared later were the result of slower growing cell lines and were more likely 
to be contaminated from any cell(s) left from the initial clone picking, clones that 
grew later were not picked. Clones that were initially positive were screened later 
since hybridoma cells are unstable. Clones that were still viable and positive for the 
specific antibody decreased to approximately one fourth the original number. The 
summary of clone selections are shown in Table 2. Two cell lines that were positive 
for one amylase antigen and negative for the other were maintained (2PE10 and
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*1 froze 24 best- lost in freezing technique; worked with 6 best-lost to fungus contaminate of 
media
*2 too low o f antibody production
*3 lost to fungus contaminate of media (same time as PI cells)
*4 fusion media had aggregates of hard media, too hard to pick clones
Figure 8
Titer assay of anti-p-amylase by solid-phase enzyme immunoassay on microwell 
immobilization. Assay run in duplicate.
■  : mouse 1; Y=0.544-0.0812xlog(X), r=0.946 
•  : mouse 2; Y=0.558-0.079xlog(X), r=0.984
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Titer assay of anti-s-amylase by solid-phase enzyme immunoassay on microwell 
immobilization. Assay run in duplicate.
■  : mouse 1; Y=1.409-0.222xlog(X), r=0.994 
•  : mouse 2; Y=1.116-0.169xlog(X), r=0.962
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2PC2 for p-amylase; 2S2E4 and 2S2F7 for s-amylase). Two other cell lines (2PC12 
and 2S1A7) that were cross reactive to both p- and s-amylase were also maintained to 
do the initial testing of the enzyme immunoassays.
4. Production of antibodies in vitro
As the hybridomas were grown to sufficient number for injection into the 
mouse to produce ascites fluid, the media that was removed and replaced with fresh 
media. The media that was removed was saved, stored at -20°C, and later purified to 
determine if a significant amount of antibody could be obtained by the in vitro 
cultivation of the cells. The amount varied from 1.4 /zg/mL to 5.7 /zg/mL of complete 
media. Two cell lines were also grown in Hybridoma Serum Free Media by Gibco 
and yielded 0 /zg/mL and 5.8 /xg/mL for 2PE10 and 2PC2, respectively. In vitro 
antibody production is summarized in Table 3.
5. Production of antibodies in ascites fluid
Ascites fluid production varied from 8 to 26 days from the intraperitoneal 
injection of the hybridoma cells with an average of 13 days. The total volume 
collected ranged from 3 mL to 17.2 mL. This figure reflects the amount collected not 
the total volume produced since some of the ascites fluid was lost during the tap. The 
average amount of fluid produced was 5.6 mL and 7.6 mL by priming with pristane 
and Incomplete Freund’s Adjuvant, respectively. The average amount of antibody 
produced was 0.56 grams/mL of ascites fluid produced. The summary of all antibody 
production is in Table 3.
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2PE10 CM 130 368 @ 2 7.4xl03 5.7x10*
SF 85 0 @ 5 0 0
Pr 14-3:16-3 6 886 @ 5 4.43 0.7383
IF 14-4 3 331 @ 5 1.32 0.44
2PC2 CM 120 94 6.8 6.4x10’ 5.3x10*
SF 43 46 5.5 2.5x10’ 5.8x10*
Pr 11-3.5:13-3.5 7 774 5 3.87 0.5529




2S1A7 CM 85 50 @ 5 2.5x10’ 2.9x10*
Pr 9-4.5:11-2.8 6 688 @ 5 3.44 0.5733
2PC12 CM 50 56 @ 5 2.8x10’ 5.6x10*




2S2F7 CM 40 0 0 0





2S2E4 CM 65 18 @ 5 9.0x10’ 1.4x10*
Pr 26-1.3:28-2.2 3.5 383 @ 5 1.92 0.549
abbreviations: (CM) complete media,
(SF) serum free media,
(Pr) ascites fluid from pristane primer,
(IF) ascites fluid from Incomplete Freund’s Adjuvant primer, 
(@) approximately
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6. Purification of antibodies
The media in which the hybridoma cells were grown and the ascites fluid were 
both purified by affinity chromatography with Protein A-Sepharose using a citrate 
buffer of pH 3.0. The elutions of 2PC2 and 2S2F7 are seen in Figures 10 and 11, 
respectively.
7. Isotyping of antibodies
All three antibodies (2PC2, 2S2F7 and 2PC12) were determined to be IgG2b 
by the Sigma ImmunoType Mouse Monoclonal Antibody Isotyping Kit.
C. Assay conditions
1. Well coating studies
Due to cycloheptaamylose’s circular structure of seven glucose units, as seen 
in Figure 12, it acts as an inhibitor of amylase. In order to coat the microwells with 
cycloheptaamylose it was necessary to attach it to a protein. This was accomplished 
by first oxidizing at least one of the hydroxyl groups to a carboxyl group and then 
connecting it to the protein by an amide linkage. The circular structure of 
cycloheptaamylose also had to be maintained to insure that it remained an inhibitor of 
amylase and did not instead become a substrate for amylase. The results of the 
oxidation of cycloheptaamylose at 8, 12, 24, 36, 42, 48 and 84 hr are shown by the 
graphs of the infrared analysis in Figures 13 and 14. The appearance of an additional 
peak at 1750 wave numbers starts to appear at 8 hr. It becomes equal in length to the 
peak at 1650 at 36 hours. This concurs with the formation of a carboxyl group, with 
the peak at 1650 due to the presence of the carbonyl group in a semiacetyl formation.
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Figure 10
The elution profile of anti-p-amylase from protein A sepharose chromatography
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Figure 11
T h e  e lu t io n  p r o f i l e  o f  a n t i - s -a m y la s e  f r o m  p r o t e in  A  s e p h a r o s e  c h r o m a t o g r a p h
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Figure 13
I n f r a r e d  a n a ly s is  o f  t h e  o x id a t io n  o f  c y c lo h e p ta a m y lo s e
A. 0 hours, B. 8 hours, C. 12 hours, and D. 24 hours
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Infrared analysis of the oxidation of cycloheptaamylose
A. 36 hours, B. 42 hours, C. 48 hours, and D. 84 hours
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The peak at 1150 concurs with the ether linkage that results in the ring structure of 
cycloheptaamylose. When the oxidation was allowed to go for 84 hr, the peak at 1650 
began to deteriorate. Oxidation time was chosen to be 36 hr since the two peaks due 
to carbonyl and carboxyl groups were equal in length, and it was only necessary to 
oxidize one hydroxyl group on cycloheptaamylose.
Of the ratios 1:1, 1:2, 1:4, and 1:8 of BSA to CHA, the highest reacting ratio 
was 1:1, as seen in Figure 15. Since the absorbance of all of the ratios was low, a 
mean of 0.156, further studies were performed to rectify this.
Activation of the carboxyl group was undertaken with carbodiimide by the 
formation of an O-acylurea. However, in an aqueous media this intermediary is 
subject to hydrolysis. The presence of N-hydroxy-succinimide (NHS) results h  the 
formation of an active ester that is more hydrolysis resistant.128 129 By increasing the 
concentration of EDC and NHS from 1 mM to 0.1 M, the readings were increased 
from a mean of 0.156 to 0.565. The best ratio of BSA to CHA was chosen to be 1:1 
at a concentration of 20 jig/well since this was the only ratio with a positive slope.
The results are shown in Figure 16.
2. Washing studies
Three washing agents were tested: deionized water, 10 mM PBS, pH 7.4, with 
and without 0.1 % Tween. Each of these was followed by an equal number of 
washings with deionized water. Figure 17 shows that, washing 7 times PBS-Tween 
followed by 7 times with deionized water gave the greatest difference between the 
sample with the antigen and the blank.
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Figure 15
Optimization of coupling oxidized cycloheptaamylose to bovine serum albumin 
with 1 mM aqueous l-ethyI-3-(3-dimethylaminopropyl)carbodiimide and 
iV-hydroxysuccinimide for assay in solid-phase enzyme immunoassay on microwell 
immobilization. Assay run twice.
■ : 1BSA.-1CHA; Y=0.176+6.7xlO'5(X), r=0.288
•  : 1BSA:2CHA; Y=0.156+2.0xl(T,(X), r=0.451
♦ : 1BSA:4CHA; Y=0.143+2.0xl0J'(X), r=0.534
a : 1BSA:8CHA; Y=0.136-9.2x10'5(X), r=0.253
























Optimization of coupling oxidized cycloheptaamylose to bovine serum albumin 
with 0.1 M aqueous l-ethyl-3-(3-dimethyIaminopropyl)carbodiimideand 
jV-hydroxysuccinimide for assay in solid-phase enzyme immunoassay on microwell 
immobilization. Assay run twice.
■  : 1BSA:1CHA; Y=0.571+2.0xl0J‘(X), r=0.266 
•  : 1BSA:2CHA; Y=0.568-2.0xl0-3(X), r=0.604 
♦ : 1BSA:4CHA; Y=0.625-6.0xlOJ,(X), r=0.793 
a : 1BSA:8CHA; Y=0.581-4.9xl0'5(X), r=0.044















Washing study on solid-phase enzyme immunoassay on microwell immobilization.
Assay run twice.
Washing agent on samples:
■  : deionized water; Y=0.307-1.6xlO'2(X), r=0.459 
•  : 10 mM PBS, pH 7.4; Y=0.267-2.0xlO-3(X), r=0.449 
♦ : 10 mM PBS, pH 7.4, with 0.1% Tween;
Y=-0.100+8.4x 10'2(X), r =0.999
Washing agent on blanks:
□  : deionized water; Y=0.103+4.2xl0'2(X), r=0.469
0 : 10 mM PBS, pH 7.4; Y=0.262-1.8xl0-2(X), r=0.554
0 : 10 mM PBS, pH 7.4, with 0.1% Tween; Y=0.138+0.0(X), r=0.999
Net difference of sample minus blank:
i:i: deionized water; Y=-0.112+3.3xl0'2(X), r=0.95 
gg: 10 mM PBS, pH 7.4; Y=-0.003+1.6xl0'2(X), r=0.686 
10 mM PBS, pH 7.4, with 0.1% Tween;
Y=-0.111 +5.0xl0'2(X), r=0.999
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The three blocking agents tested were BSA, OVA, and skim milk in coating 
solution at the following concentrations: 0.3%, 0.5%, 1%, 3%, and 5%. The results 
are shown in Figure 18. BSA and skim milk gave the greatest difference between the 
sample with the antigen and the blank with BSA being slightly better. OVA appeared 
to inhibit the activity of the antigen since little difference was observed between the 
sample and the blank. Since both 0.5% and 3% gave the best net difference between 
the sample and the blank, they were further tested at room temperature and 37°C.
The results are in Figures 19-22. Of these testings, 0.5% BSA in coating solution for 
45 min at 37°C was chosen for blocking the unbound spaces on the polystyrene 
surface.
4. Sample studies
a. Sample diluent study
The diluents investigated consisted of 10 mM PBS, pH 7.4; PBS-SM; and 10 
mM PBS, pH 7.4, with 8 mmol/L CaCl2. Although chloride ions are necessary for
amylase activity, and calcium ions are necessary for the structural integrity of the
enzyme,4 protein appears to also be necessary to maintain the binding conditions of 
amylase to the inhibitor CHA. Figure 23 shows that PBS-SM was the best diluent.
b. Sample size study
The abnormal control sera used to test the diluent, as seen in Figure 23,
showed lower activity undiluted than when diluted 1:2 or 1:4. The 1:4 dilution in fact
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Figure 18
Study of dilutions of blocking agents on solid-phase enzyme immunoassay on 
microwell immobilization. Assay run at room temperature twice.
Blocking agent with samples:
■  : 10 mM PBS, pH 7.4, with BSA;
•  : 10 mM PBS, pH 7.4, with 0.1% skim milk;
♦ : 10 mM PBS, pH 7.4, with OVA
Blocking agent with blanks:
□  : 10 mM PBS, pH 7.4, with BSA;
O: 10 mM PBS, pH 7.4, with 0.1% skim milk;
0 : 10 mM PBS, pH 7.4, with OVA
Net difference of sample minus blank:
I::: 10 mM PBS, pH 7.4, with BSA;
$|$: 10 mM PBS, pH 7.4, with 0.1% skim milk
£ :  10 mM PBS, pH 7.4, with OVA
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
76
05 CD N  O
d o d o
(luu QSfr) e o u e q jo s q v











Blocking incubation study of 0.5% bovine serum albumin at room temperature 
on solid-phase enzyme immunoassay on microwell immobilization.
Assay run twice.
■  : sample; □ : blank; sample - blank
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Blocking incubation study of 0.5% bovine serum albumin at 37°C on solid-phase
enzyme immunoassay on microwell immobilization. Assay run twice.
■  : sample; □: blank; $j$: sample - blank
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Blocking incubation study of 3% bovine serum albumin at room temperature on
solid-phase enzyme immunoassay on microwell immobilization. Assay run twice.
■  : sample; □ : blank; sample - blank
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Blocking incubation study of 3% bovine serum albumin at 37° C on solid-phase
enzyme immunoassay on microwell immobilization. Assay run twice.
■  : sample; □: blank; sample - blank
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Sample diluent study on solid-phase enzyme immunoassay on microwell.
Assay run twice.
Diluents: ■ : 10 mM PBS, pH 7.4;
Y=0.587+2.3‘5(X), r=0.074 
•  : 10 mM PBS, pH 7.4 with 8 mM CaCl2;
Y=0.572-2.1xl04(X), r=0.371 
♦ : 10 mM PBS, pH 7.4 with 0.1% skim milk;
on data points 1-85: Y=0.246+4.3xl0'3(X), r=0.926
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showing the highest absorbance. The fact that the activity increases with a smaller 
sample size was confirmed by testing twofold dilutions of the normal control sera 
along with the abnormal control sera, seen in Figure 24. From these results the 
sample size was reduced to 40 /tL instead of 200 /iL/well. A 1:5 dilution of each 
sample was made with the PBS-SM (40 piL sample plus 160 ixL PBS-SM) when 
performing the assay.
c. Sample incubation study
Samples of normal control serum and blanks of the diluent were incubated at 
room temperature for 30, 45, 60, 90, and 120 min. These results, plus the net 
difference between the sample and blank, are shown in Figure 25. This study was 
also performed at 37°C, and the results are illustrated in Figure 26. Room 
temperature provided the best readings with a 60 min incubation determined as the 
best incubation time.
5. Antibody-HRPO studies
The HRPO conjugated antibodies (2PC12, 2PC2, and 2S2F7) were serially 
diluted with 10 mM PBS, pH 7.4, and incubated in a moist chamber at room 
temperature and 37°C for 30, 45, 60, 90 and 120 min. The results of the serial 
dilutions of the HRPO-antibodies are seen in Figures 27-29. From these 2PC12 was 
diluted 1:750 and used for testing the assay procedure. A 1:600 dilution was made for 
2PC2, and a 1:700 dilution was made for 2S2F7. The results of incubation times of 
30, 45, 60, 90 and 120 min at room temperature are shown in Figure 30. Figure 31 
shows the results of the 37°C incubation temperature at the same incubation times.
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Figure 24
Sample size study on solid-phase enzyme immunoassay on microwell.
Assay run twice.
■  : normal control; Y=0.797-2.1xl0'3(X), r=0.901 
•  : abnormal control; on points 21-85: Y=0.655 +3.0xl0‘3(X), r=0.992
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Sample incubation study at room temperature on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■  : sample; □: blank; $$: sample - blank






(w u  ost?) e o u e q jo s q v







Sample incubation study at 37° C on solid-phase enzyme immunoassay on
microwell immobilization. Assay run twice.
■  : sample; □: blank; sample - blank
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Antibody dilution study of cross reacting anti-p&s-amylase-HRPO (2PC12) on 
solid-phase enzyme immunoassay on microwell immobilization.
Assay run in duplicate.
■  : sample; Y=0.852+1.0xl0J'(X), r=0.847 
□  : blank; Y=0.570-8.7xl0-5(X), r=0.845 
sample - blank;
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Antibody dilution study of anti-p-amylase-HRPO (2PC2) on solid-phase enzyme 
immunoassay on microwell immobilization. Assay run in duplicate.
■  : sample; Y=1.136-8.9xl04(X), r=0.940 
□  : blank; Y=0.836-7.6xl0^(X), r=0.860 
3$: sample - blank
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Antibody dilution study of anti-s-amylase-HRPO (2S2F7) on solid-phase enzyme 
immunoassay on microwell immobilization. Assay run in duplicate.
■  : sample; Y=1.127-5.5xl04(X), r=0.827 
□  : blank; Y=0.470-1.5xl04(X), r=0.450 
sample - blank
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Antibody incubation study at room temperature on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■ :  sample; □ :  blank; $$■: sample - blank
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Antibody incubation study of antibody at 37°C on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■  : sample; □ : blank; sample - blank
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The antibody appeared to bind better at 37°C than room temperature; therefore, a 45 
min incubation at 37°C was selected as the best incubation for the antibody-HRPO.
6. Indicator system studies
The results of solution A and B incubation at 5, 10, 15 and 20 min with serial 
dilutions of p-amylase and 2PC2-HRPO are shown in Figure 32. The results of 
incubation with s-amylase and 2S2F7-HRPO are shown in Figure 33. Color 
development was best between 15 and 20 min.
D. Study of the performance characteristics of the enzyme immunoassay
1. Linearity studies
The assay procedure that was employed in testing for p-amylase and s-amylase 
is summarized in Table 4. The results of the serial dilution of p-amylase and 2PC2- 
HRPO are seen in Figure 34. Pancreatic amylase determinations were linear from 8 
U/L up to the 1000 U/L tested. Salivary amylase determinations were linear from 16 
U/L to the 1000 U/L tested. The linearity of 2S2F7 are shown in Figure 35.
2. Limit of detection studies
Twenty blanks were run simultaneously with standards for p-amylase and s- 
amylase. The standard deviation calculated for p-amylase was 0.064 and for s-amylase 
was 0.047. Following the recommendation of the International Federation of Clinical 
Chemistry (IFCC), the limits of detection equal 2.6 x S.D., which are 0.166 and
0.122 for p-amylase and s-amylase, respectively. From the standard curve which was 
run in the same assay with the blanks, the limits of detection were determined to be 8 
U/L for p-amylase and 16 U/L for s-amylase.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 32
Color development time study of p-amylase solid-phase enzyme immunoassay on 
microwell immobilization. Assay run twice.
Incubation times:
■  : 5 min; Y=0.216+8.4xl0^(X), r=0.941
•  : 10 min; Y=0.428+1.6xlO'3(X), r=0.912
♦ : 15 min; Y=0.535+2.1xl0'3(X), r=0.980 
a : 20 min; Y=0.603 +2.7xl0'3(X), r=0.987 
slope vs time: Y=3.5xlO'5+3.3xlOJ‘(X), r=0.932
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Color development time study of s-amylase solid-phase enzyme immunoassay on 
microwell immobilization. Assay run twice.
Incubation times:
■  : 5 min; Y =0.277+l.lxl0 ‘3(X), r=0.946
•  : 10 min; Y=0.341+3.2xl0‘3(X), r=0.979
♦ : 15 min; Y=0.383+3.3xl0‘3(X), r=0.947 
a : 20 min; Y=0.583+4.9xl0'3(X), r=0.910 
slope vs time: Y=2.5xlO'4+2.3xlO'4(X), r=0.953
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Table 4. Summary of the assay conditions for enzyme immunoassay 
for p-amylase and s-amylase determination
substance time temperature concentration amount
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Figure 34
Linearity of anti-p-amylase-HRPO (2PC2) on solid-phase enzyme immunoassay 
on microwell immobilization. Assay run three times.
Y=0.181 +0.3661og(X), r=0.972
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Linearity of anti-s-amylase-HRPO (2S2F7) on solid-phase enzyme immunoassay 
on microwell immobilization. Assay run three times.
Y=-0.092 +0.570Iog(X), r=0.933
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Twenty replicates of commercially prepared pooled normal serum and 
abnormal serum were assayed in the same experiment for p-amylase and s-amylase. A 
summary of the statistical analysis of the assays are in Table 5 for p-amylase and 
Table 6 for s-amylase. The coefficient of variation (C.V.%) for p-amylase normal 
serum was 7.79%, and 6.28% for abnormal sera. For s-amylase the C.V.% was 
9.42% and 9.29% for normal and abnormal sera, respectively.
4. Cross reactivity studies
Initial screening of 2PC2 showed an absorbance reading of 0.454 against a 
blank of complete media with p-amylase precoated on the wells at a 
concentration of 1 /zg/mL and 0.006 against a blank of complete media with s- 
amylase precoated on the wells at a concentration of 1 /zg/mL. Original screening of 
2S2F7 showed an absorbance reading of 0.404 against a blank of complete media with 
s-amylase precoated on the wells at a concentration of 1 /zg/mL and 0.032 against a 
blank of complete media with p-amylase precoated on the wells at a concentration of 
1 uglmL. Later assays using s-amylase and 2PC2 and p-amylase and 2S2F7 resulted 
in determinations below the level of detection.
£ . Validation studies
Thirty-two serum patient samples along with a normal control, and abnormal 
control were analyzed on Immulon 1 wells previously coated with 20 /zg/well 
CHA:BSA that had been blocked with 0.5% BSA in coating solution for 45 min at 
37°C. The samples were diluted 1:5 with PBS-SM, and 200 /zL was added to each
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well. These were incubated at room temperature for 60 min. They were then washed 
seven times with PBS-Tween followed by seven times with deionized water. The 
samples were incubated for 45 min at 37°C with 200 pL of each of the two 
antibodies, 2PC2-HRPO and 2S2F7-HRPO, that had been diluted to 1:600 and 1:700 
respectively. The wells were again washed, and the two color developing solutions, A 
and B, were added. When a blue color developed, the color reaction was stopped with 
the addition of 2 N H,S04. The resulting yellow color was read on the microplate 
reader at 450 nm. The summary of admitting diagnosis, total amylase, cellulose 
acetate electrophoresis and E1A for p-amylase and s-amylase are shown in Table 7. 
Linear regression of the results gave an intercept of 82.060, a slope of 0.460 and 
correlation coefficient of 0.820 for p-amylase; however, samples number 6, 77, and 
201 included P3 amylase which is not detected by the EIA. Using just the values of P, 
and P2 for the p-amylase value for electrophoresis, the intercept was 21.310, the slope 
was 1.152, and the correlation coefficient was 0.920. For s-amylase the intercept 
was -1.25, slope 1.15, and correlation coefficient was 0.867.
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Table 7. Comparison of electrophoresis and enzyme immunoassay of p-amylase 





















2 gun shot 
wound neck
153 15 361 138 175
3 beaten head &  
face
524 <10 31 524 656









917 641 1140 276 224
20 mesenteric
ischemia
193 48 51 145 120
22 pancreatitis 157 110 138 47 40
26 70 35 46 35 76
29 shingles
pancreatitis
127 57 248 95 75
34 pneumonia 625 <10 33 625 527
77 coronary 
artery disease
165 <10  
135 P3
13 <10 <16
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202 gun shot 
wound
267 <10 14 267 <16
203 bums 67 27 15 40 29
204 shortness of 
breath
97 49 32 49 <16
206 abdominal pain 98 <10 11 98 99
207 transplant 118 <10 9 118 126
208 pain crisis 
vasoocclusive
35 25 25 10 < 16
209 chest pain 
? M I acute 
gout
167 117 132 50 243
210 chest pain 
? M I acute 
gout
356 249 272 109 80
211 pancreatitis 210 158 100 52 34
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213 sepsis renal 
failure
210 84 57 126 66
214 pancreatitis
hepatitis?
679 475 474 204 212
57 abdominal pain 94 47 64 47 60
216 flu 3 days 24 12 < 8 12 <16
217 leukemia 195 137 30 58 70
218 leukemia 234 129 125 105 80
243 aneurism 162 65 74 97 96
87 pancreatitis? 152 76 53 76 25
219 ? M I chest 
pain
66 26 32 40 32
224 acute
cholecystitis
155 62 265 93 100
225 stomach pain 75 30 239 45 33
VI normal
control
80 32 37 48 44
V II abnormal
control
340 170 129 170 250





Normal pancreatic tissue obtained from autopsy was purified by various other 
procedures that included (NH4)2S04 precipitation, acetone and sodium acetate 
extraction; however, the procedure outlined in the methodology gave the best 
yield.119,120121 The main essential was that all of the extractions had to be performed as 
quickly as possible while maintaining the enzyme’s stability in a concentrated solution 
of pH 7.0 to 8.0, and stored at 4°C or less.
2. Amylase standards
The purified p-amylase was stored at -80°C with some smaller aliquots at 
-20°C and 4°C. Activity did decrease over the period of a year. The -80°C preserved 
the amylase best while 4°C preserved it the least. Dilutions of the enzyme were later 
added to human serum with an amylase value of 6 U/L for the establishment of the 
standard curves. Storage of the enzyme appears to be better in a higher protein media 
than the 10 mM PBS, pH 7.4, buffer. The p-amylase and s-amylase standards were 
assayed first in the PBS-SM diluent; however, their activity was not as great as when 
they were added to either serum free amylase, serum that had been extracted with 
CHA-Sepharose, or serum with an amylase level of less than 10 U/L. The serum with 
the amylase level of less than 10 U/L gave the best reactivity for the isoamylases. 
Electrophoresis of the p-amylase and s-amylase in 10 mM PBS, pH 7.4, were
104
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
105
performed. The p-amylase sample gave one distinct sharp band. The s-amylase had a 
few much smaller peaks on the scan of the cellulose acetate electrophoresis. The s- 
amylase was purchased commercially and not subjected to Protein A Sepharose 
purification. Of the two assays, s-amylase determinations had a higher detection limit, 
a lower correlation coefficient, and the C.V.% for the normal and abnormal control 
sera were higher than for p-amylase.
3. Chemical properties
The chemical properties of amylase afford an unusual opportunity for its 
quantification. Its molecular weight of 54,96712 enables it to be used as an antigen in 
an EIA sandwich assay; thus, it can be used to elicit an antibody response without 
having to be attached to a larger protein as a carrier. Hence, the opportunity for 
incorporating it into EIA procedures is possible. Pancreatic amylase and s-amylase 
differ by 1% in their amino acid sequence.8 This difference is only slight but is 
sufficient to differentiate the two isozymes by electrophoresis.10 Furthermore, 
production of specific monoclonal antibodies against each is becoming more
SUCCeSSful 76.77.112.U3-116.118
Because amylase is an enzyme, its enzymatic reactivity has been utilized for 
assay procedures.12,67'69 Additionally, amylase’s binding affords another opportunity 
for its determination. Robyt and French demonstrated that the active binding site of 
amylase binds a maximum of five glucose units. In addition, binding of the substrate 
appears to be polar with the reducing end closest to the catalytic group.131
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B. Cycloheptaamylose
The substrate/inhibitor binding characteristics of amylase were the basis of the 
development of this EIA since cycloheptaamylose is composed of seven glucose units 
in a circular structure. It is a perfect inhibitor of amylase, is inexpensive and is 
readily available. The unique properties of CHA enabled it to be used not only as the 
means of purifying p-amylase but also as a means of developing a unique sandwich 
assay. The principle of the assay is based on the CHA-amylase-antibody-HRPO 
complex being formed. The patient sample is added to a microwell precoated with 
CHA. The amylase (antigen/enzyme) binds to the CHA which is bound to the solid 
phase (microwell) during incubation, then later the excess amylase is washed off. The 
enzyme labeled antibody is allowed to incubate with the complex, then the excess 
labeled antibody is washed off. The indicator system consisting of a substrate and 
chromogen is added, and the color develops proportionally to the amount of amylase 
in the sample, as demonstrated in Figure 36.
Traditionally, in the heterogeneous noncompetitive enzyme immunoassay or 
sandwich assay, an antibody is coated onto the solid phase. The sample with the 
antigen is allowed to react, then the excess is washed off. A second antibody which is 
labeled with an enzyme attaches to a different site on the antigen. The excess enzyme 
labeled antibody is washed off, and the substrate and chromogen are added.
The resulting color reaction from the addition of the substrate and chromogen is 
directly proportional to the amount of antigen in the sample.
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Figure 36
Principle of the enzyme immunoassay for p-amylase or s-amylase
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In order to attach CHA to the microwell it was necessary to couple it to a 
protein first. The protein, in turn, was then adsorbed on to the surface of the 
polystyrene surface of the microwells. It was first necessary to convert at lest one of 
the primary alcohols to a carboxylic acid and then, by an amide linkage, to couple it 
to the protein. Several means of oxidation of the CHA and its subsequent purification 
were attempted. The nitric acid mixture decomposed the DEAE cellulose column 
midway through its elution.127 A method to couple the CHA by using sodium 
periodate and dioxane to 6-aminohexanoic acid was also attempted. This would 
produce a compound which would act as a linker to the protein. This required the 
use of size exclusion chromatography utilizing Sephadex G-10-120. Likewise, 
coupling it to chloroacetic acid and then OVA and also BSA was also unsuccessful.131 
Finally, the oxidation of a primary alcohol to a carboxylic acid was successful using 
the sodium nitrite-nitric acid mixture; however, care had to be taken, as the resulting 
brown nitrous dioxide gas is rather toxic. The resulting carboxyl group enabled CHA 
to be coupled by an amide linkage to BSA by first activating it with carbodiimmide 
resulting in an O-acylurea. Essential to this coupling was the presence of the NHS 
which helped to prevent the hydrolysis of the activated carboxylate of CHA. The first 
attempts at the BSA coupling were unsuccessful until NHS was added in the reaction 
mixture at sufficient strength.128 The BSA:CHA conjugate was then able to be coated 
onto the polystyrene surface of the microwells; thus, the enzymatic function of the 
antigen, amylase, resulted in its attachment to the well. The next part of the reaction
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depended on the antigenic properties of amylase with the utilization of the specific 
antibody against p-amylase or s-amylase.
C. Antibody production
1. Cell fusion
The first cell fusion gave the greatest yield of clones: 468! But this number of 
clones was very difficult to maintain for one person. A fusion resulting in 100 clones 
is an ideal number. Since newly formed hybridomas are highly unstable, it is 
probably a waste of time to screen the clones for positive antibody production for the 
first 10 days since some will either cease to be viable or stop antibody production. It 
was observed that only one-fourth of the cells from those initially picked remained 
viable and produced antibodies specific for the antigen. The maintenance of 
hybridomas is particularly tedious. Aseptic technique has to be maintained at all 
times. Initially, the incubator was washed with a 2% lysol solution and then rinsed 
with ethanol. The water that was kept in the bottom to maintain humidity was 
changed weekly. The outside of the flasks were rinsed with 70% ethanol prior to 
placing them in the hood for either transfer of cells or the addition of new media. 
Gloves were worn and washed with 70% ethanol before handling the flasks. Flasks 
were flamed prior to opening and again before entering with a sterile pipette or 
pouring. Even with all of these precautions, contamination did occur resulting in the 
loss of two cell lines. The fungal infection was the result of the addition of new media 
that was contaminated. It is advisable to never change all the cell flasks or wells of a 
growing cell line at the same time.
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The initial freezing technique for maintaining cells proved unsuccessful; hence, 
the back up lines from the first fusions were lost. Initially, cells were placed at -20°C 
for 2 hrs, then -80°C for 4 hrs, then transferred to the gaseous phase of liquid 
nitrogen. Later, this was changed to transferring the cells immediately into gaseous 
phase of liquid nitrogen. The amount of DMSO was also reduced from 10% to 6% 
with 20% FBS in serum free media. Recovery of frozen cells was usually from 50 to 
75%.
2. Ascites fluid production
Initially, ascites fluid production was only minimally successful. Other strains 
of mice that were tried were Balb/CJ and a"CFl"; both of these yielded ascites fluid 
only in one out of ten attempts. The mouse strain was changed to the Balb/CByJ, and 
the concentration and amount of cells injected were increased. It is also essential that 
the cells are in the log phase, not in the stationary phase, of growth when they are 
injected. Hybridoma cells are rather large and fragile; hence, they were drawn into 
the syringe without a needle. A 25 G needle was later placed on the syringe for 
injection. When a larger gauge needle was used, the cell solution tended to leak out of 
the peritoneal cavity. After the ascites fluid was produced, as was evident by the 
swelling of the abdomen of the mouse, it was also possible to recover hybridoma cells 
from the peritoneal cavity. The ascites fluid contained both hybridoma cells and 
fibroblast which eventually died. The media needed to be changed daily since 
contamination was at a greater risk with the ascites fluid due to the collection 
technique. Attempts at drawing the ascites fluid from the peritoneal cavity into a
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syringe proved unsatisfactory. Invariably, the intestine or peritoneum would block the 
bevel of the needle. The Incomplete Freund’s Adjuvant, which gave slightly higher 
volume yield of ascites fluid, required 7-10 days inoculation prior to cell infusion.
This was either advantageous if  hybridomas were not in sufficient quantity for 
injection or disadvantageous because of the extra time required. Since sufficient 
antibody was purified from the pristane primed mice, the two highest ascites fluids 
produced were frozen but never extracted to determine the yield of antibody.
D. Diagnostic groups
The two groups with the highest incidence of acute pancreatitis are those 
patients with gallstones and alcoholism.25,26,27 The high incidence association with 
gallstones is often the result of the gallstone blocking the ampulla of Vaater, which is 
shared by the bile duct in some individuals. Other groups are also predisposed to 
producing a pancreatitis such as those individuals suffering from an infarction, 
ischemia,39 and cardiopulmonary bypass surgery (which also can have a 
hyperamylasemia without a pancreatitis),41 The administration of calcium chloride 
appears to be dose related with pancreatic cellular injury.43 This is a curious 
phenomena since both calcium and chloride are necessary for amylase activity. 
Ironically, surgical procedures in and around the pancreas, such as endoscopic 
retrograde pancreatography,51 that are often performed for treatment and/or 
diagnosing pancreatitis are known to elevate amylase levels and have also been known 
to induce a pancreatitis. The highest levels of amylase, greater than 1000 U/L, are 
seen in gallstone related pancreatitis.29
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Increased s-amylase levels frequently associated with cardiac surgery are often 
associated with the severity of pleural effusion.44 Total body irradiation also increases 
the quantity of serum s-amylase.24
Reduced p-amylase is associated with chronic pancreatitis79 and carcinoma of 
the pancreas.66
Renal failure is associated with an increase in both amylase isozymes.46 
Trauma to any organ of amylase predominance (parotid gland, submandibular gland 
and the pancreas) will cause an increase in the respective amylase levels.
E. Human serum samples
1. Sample diluents
Sample diluent was of primary concern in this EIA procedure since the 
determination of amylase not only depended on the antigenic properties of amylase 
but on its enzymatic properties as well. It is not surprising that chloride ions were 
necessary for the enzymatic reactivity of the amylase since this is a well documented 
fact.4 However, the necessity of placing the amylase standard in human serum to 
optimize the reaction was. Although high concentrations of the protein in human 
serum, as was seen in undiluted specimens, reduced the binding of amylase, it was 
necessary to optimize the reaction of the standards. This was evident by the increased 
activity of the standards in human serum. The patient samples, on the other hand, had 
to be diluted with the diluent by at least 1:4. A 1:5 dilution was chosen to reduce the 
interference of the serum protein in the reaction. This was advantageous in that the
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sample size was reduced from 200 /zL to 40 /zL, with the remaining 160 /zL being 
diluent.
2. Enzyme immunoassay of human serum samples
The isoamylase EIA, as it was performed on patient samples, was consistent 
with the admitting diagnosis of patients with "pancreatitis" that also showed increased 
amylase and lipase levels. In one case, the EIA showed an increase that the 
electrophoresis did not. Of the admitting diagnoses that were most probable to be 
correlated with increased s-amylase values: "beaten head and face", "gun shot wound 
neck", and "pneumonia", all showed increased s-amylase by electrophoresis and EIA. 
Unrelated admitting diagnoses such as "burns", "aneurism", "leukemia", and "flu" 
exhibited normal p-amylase and s-amylase levels by both methods. There were a few 
specimens that showed poor correlations. This was probably due to the fact that some 
patient samples were kept for a year at 4°C. Their amylase activity did not decrease; 
however, when they were tested by the EIA method, very high values were obtained 
for either p-amylase and/or s-amylase. This was probably the result of non specific 
binding of other serum constituents.
The source of p-amylase for the immunization and enzyme standards for the 
EIA procedure was normal pancreatic tissue. This is certainly a good source for 
isoamylase P, and P2; however, it does preclude the detection of P3 isoamylase. This 
was the case in three of the patient samples. P3 isoamylase determined by cellulose 
acetate electrophoresis has a positive efficiency of 93% and a negative efficiency of 
100%.81 Thus, the value of incorporating P3 into an immunoassay procedure is worth
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considering. However, it has not been reported that P3 isoamylase is present without 
an increased total p-amylase; therefore, the main advantage of measuring P3 
isoamylase levels is specificity not sensitivity. Pancreatic amylase levels appears to be 
more sensitive to the diagnosis of pancreatitis than total amylase levels. A method for 
determining P3 levels would be even more specific for acute pancreatitis.79
3. Electrophoresis
Electrophoresis procedures which are currently used for determining the levels 
of specific isoenzymes for amylase are labor intensive, and only a few specimens can 
be analyzed at one time. A typical assay employs two standards and two controls; 
therefore, out of an eight sample strip, only four samples can be run at once. The 
turn-around-time for the assay is also long. The electrophoresis alone takes 1.5 hrs 
plus 1.5 hrs of incubation with the substrate-dye. Then the gels need to be cleared, 
dried and scanned. Also, interpretation of the results obtained by electrophoresis is 
very subjective. In scanning the strip, the placement on the scanner can greatly 
influence the results. Often during the run, the samples do not move in a straight line 
but migrated at an angle. It is necessary to visually check the bands to insure that the 
scanner is not at an end of one of the bands instead of the middle. The bands have to 
be compared manually to the standards in the run to interpret which peak is which 
isoenzyme. The scanner does not automatically interpret which peak is which 
isoenzyme. The P3 band can be confused with the S, band particularly if  the level of 
s-amylase is reduced. Thus, marking the results of the scan for the integration of the 
percentages of each isoenzyme is, again, a subjective determination. Values of the
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amount of any isoenzyme can easily vary 20%. Scans of the electrophoresis of several 
patient’s samples are illustrated in Figure 37.
E. Summary
Tests that utilize enzymatic activity were the first improvement on the early 
colorimetric methods. The introduction of fluorescent methodology offered increased 
sensitivity, but they had the problem of contamination and high backgrounds. The 
introduction of radioimmunoassays was a major advancement in clinical chemistry in 
its sensitivity and specificity. However, these had inherent problems that were not 
initially obvious. With increased concern about the environment and safety in the 
work place for employees, the use of radioactive isotopes fell into disfavor.
The development of polyclonal antibodies and EIA methods have made the 
possibility of detecting nanogram levels of a substance available. Enzyme 
immunoassay procedures have advantages over colorimetric test for sensitivity and 
specificity. They also have advantages over radioimmunoassays which require special 
storage precautions, have limited shelf-lives, and require disposal of radioactive 
waste. Many of the enzyme dependent assays have the disadvantage that there are 
outside sources of the enzyme in the indicator system. This is the case in tests 
employing the NAD+/NADH system. If a suitable blank is not part of the assay 
system, the high background can lead to erroneous results. Currently, the use of 
monoclonal antibodies adds the advantage of greater specificity. The old problems of 
hemolysis, lipemia, and bilirubin interference are not the concern that they once were.
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Figure 37
Electrophoresis of human serum samples
A Patient 26, B patient 208, C Patient 29, D Patient 201
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Amylase determinations have proven to be a sensitive indicator for detecting 
pancreatitis. Pancreatic amylase determinations appear at present to be the most 
sensitive indicator of pancreatitis.79 The possibility of incorporating a monoclonal 
specific for P3 isoamylase is worth pursuing. With the incorporation of EIA specific 
for p-amylase, the sensitivity is not only enhanced but specificity is also increased. 
Pancreatic amylase and s-amylase determinations have the possibility of being 
automated, thus easily incorporated into the clinical laboratory. Initially, the value of 
isoamylase EIA determination is in its specificity in detecting pancreatitis; however, it 
can also help in distinguishing a pancreatitis from other causes of increased amylase 
levels. Pancreatic amylase measurements by EIA becomes particularly advantageous 
with the need for a short turn-around-time. This p-amylase EIA method can be used 
as a diagnostic test with an assay time length of 2 hours under optimized conditions. 
This could probably be shortened to 1 hour with the advantage that it can be 
automated. Hospital laboratories do not perform isoamylase determinations as the 
electrophoresis method is too costly and time consuming. Instead, they are sent to a 
reference laboratory which further increases the turn-around-time. The equipment for 
performing automated EIA procedures is already present in most sizeable hospital 
laboratories. Therefore, the incorporation of isoamylase measurements by EIA is a 
feasible possibility for the near future.
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Complete medium (100 mL):
deionized water 75 mL
FBS (HI) 10 mL
RPMI 1640 with glutamine (10X) 1.04 g
HT (50X) 2 mL
NaHC03 (7.5%) 2.2 mL
P/S (100X) 1 mL
Serum free media (100 mL)
deionized water 88 mL
RPMI 1640 with glutamine (10X) 1.04 g
NaHCOj (7.5%) 2.2 mL
NaOH (1 N) 0.3 mL
P/S (100X) 1.0 mL
The pH was adjusted on the above two media with 1 N HC1 to 6.8-7.0; then 
brought to volume with sterile distilled water. Media was filtered through a 
0.22 fxm filter unit into sterile 100 mL bottles and stored in the refrigerator. 
When it was needed for use,it was warmed in a 37°C water bath.










2 g methylcellulose + 50 mL distilled H20; autoclaved for 15 min at 15 psi
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Polyethylene glycol (PEG)
1.5 g PEG is autoclaved for 15 min @ 15 psi; then 1.5 mL serum free 
medium was added when PEG was warm.
Solution T (15 mL)
Fetal Bovine Serum 10 mL
HAT (100X) 1 mL
LPS (lipopolysaccharide) 0.2 mL
(4 mg/mL serum free IMDM)
thymocytes 2 x 108
2X IMDM 1.4 mL
distilled water 2.4 mL
Thymocyte suspension
Thymocytes were obtained as previously described and stored in complete 
medium at 4°C in a concentration of 1 X 108 cells. For a clone in a 96 well 
dish, 250 (iL of thymocyte suspension containing 104 - 10s cells/mL in 
complete medium were used. Microwells were fed with 25 ^L/well of the 
thymocyte suspension at least once a week for growing clones.
MC-IMDM
Four grams of methylcellulose in 100 mL of sterile distilled water plus 100 
mL sterile 2X IMDM. It may be stored at -20°C for up to 6 mo.
Protein A elution buffer
Dissolve 5.46 g citric acid monohydrate (52 mM) and 3.28 g Na2HP04*7H20 
(24.5 mM) in deionized water to a final volume of 500 mL. Adjust pH to 3.0 
with 1.0 N NH4OH.
Substrate solution
The substrate solution (solution A) contained 2% (w/v) hydrogen peroxide in 
0.1 M citric acid and 0.1 M sodium phosphate, pH 5.0. The solution was 
stored at 4°C.
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Chromogen solution
The chromogen solution (solution B) was prepared by dissolving 20 mg 3, 3’ , 
5, 5’-tetramethylbenzidine (TMB) completely in 1.0 mL DMSO and then 
adding, 10 mL of glycerol, 40 mL methanol and finally bringing it to 100 mL 
volume with distilled water to a final concentration of 0.2 mg/mL. The 
chromogen solution was stored at 4°C in a brown bottle.
Amylase screening solutions
Stock Substrate Solution
Dissolve 100 mg amylose (50 g/L) in 2 mL of dimethylsulfoxide by stirring at 
80°C, in a water bath. Store at 4°C.
Working Substrate Solution
Mix 100 uL stock substrate solution in 4.9 mL 50 mM Tris buffer, pH 8.5. 
Make fresh when needed (1 g/L).
Iodine Stock
Dissolve 4 g KI in 50 mL deionized water. Dissolve 100 mg I2. Bring to 100 
mL with deionized water. Store in a plastic brown bottle at 4°C
Iodine Working Solution
Mix 20 mL stock iodine solution with 170 mL deionized water. Add 10 mL 
glacial acetic acid. Store in a plastic brown bottle at 4°C.
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